BioLife Solutions (BLFS) 10-Q 15 Nov 21 2021 Q3 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	9 Months Ended
	Sep. 30, 2021	Nov. 09, 2021
Document Information [Line Items]
Entity Central Index Key	0000834365
Entity Registrant Name	BIOLIFE SOLUTIONS INC
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2021
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2021
Document Transition Report	false
Entity File Number	001-36362
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	94-3076866
Entity Address, Address Line One	3303 MONTE VILLA PARKWAY, SUITE 310
Entity Address, City or Town	BOTHELL
Entity Address, State or Province	WA
Entity Address, Postal Zip Code	98021
City Area Code	425
Local Phone Number	402-1400
Title of 12(b) Security	BioLife Solutions, Inc. Common Shares
Trading Symbol	BLFS
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		41,646,916

Unaudited Condensed Consolidate

Unaudited Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Current assets:
Cash and cash equivalents	$ 75,098	$ 90,403
Restricted cash	53	53
Accounts receivable, trade, net of allowance for doubtful accounts of $287 and $85 as of September 30, 2021 and December 31, 2020, respectively	20,232	8,006
Inventories, net	29,696	11,602
Prepaid expenses and other current assets	5,426	4,648
Total current assets	130,505	114,712
Assets held for rent, net	10,086	4,705
Property and equipment, net	17,462	10,120
Operating lease right-of-use assets, net	17,157	9,675
Financing lease right-of-use assets, net	476	17
Long-term deposits and other assets	386	230
Investments	4,372	5,872
Total intangible assets, net	155,011	31,049
Goodwill	223,936	58,449
Total assets	559,391	234,829
Current liabilities:
Accounts payable	14,296	3,672
Line of credit	2,161	0
Accrued expenses and other current liabilities	12,057	4,755
Lease liabilities, operating, current portion	2,648	1,107
Lease liabilities, financing, current portion	146	8
Debt, current portion	1,771	614
Warrant liability, current portion	0	2,780
Contingent consideration, current portion	2,714	2,637
Total current liabilities	35,793	15,573
Contingent consideration, long-term	5,524	4,515
Lease liabilities, operating, long-term	15,047	8,757
Lease liabilities, financing, long-term	329	12
Debt, long-term	6,122	655
Deferred tax liabilities	7,269	0
Other long-term liabilities	48	71
Total liabilities	70,132	29,583
Commitments and Contingencies (Note 12)
Shareholders’ equity:
Preferred stock, $0.001 par value; 1,000,000 shares authorized, Series A, 4,250 shares designated, and 0 shares issued and outstanding as of September 30, 2021 and December 31, 2020	0	0
Common stock, $0.001 par value; 150,000,000 shares authorized, 41,444,191 and 33,039,146 shares issued and outstanding as of September 30, 2021 and December 31, 2020, respectively	41	33
Additional paid-in capital	579,929	302,598
Accumulated other comprehensive loss	(163)	0
Accumulated deficit	(90,548)	(97,385)
Total shareholders’ equity	489,259	205,246
Total liabilities and shareholders’ equity	$ 559,391	$ 234,829

Unaudited Condensed Consolida_2

Unaudited Condensed Consolidated Balance Sheets (Parentheticals) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Accounts receivable, allowance for doubtful accounts	$ 287	$ 85
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	1,000,000	1,000,000
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, authorized (in shares)	150,000,000	150,000,000
Common stock, issued (in shares)	41,444,191	33,039,146
Common stock, outstanding (in shares)	41,444,191	33,039,146
Series A Preferred Stock [Member]
Preferred stock, shares designated (in shares)	4,250	4,250
Preferred stock, issued (in shares)	0	0
Preferred stock, outstanding (in shares)	0	0

Unaudited Condensed Consolida_3

Unaudited Condensed Consolidated Statements of Operations - USD ($)	3 Months Ended				9 Months Ended
	Sep. 30, 2021		Sep. 30, 2020		Sep. 30, 2021		Sep. 30, 2020
Revenue	$ 33,800,000	[1]	$ 11,279,000	[2]	$ 81,851,000	[2]	$ 33,361,000	[2]
Costs and operating expenses:
Research and development	3,219,000		1,725,000		8,250,000		4,865,000
Sales and marketing	4,065,000		1,588,000		9,228,000		4,530,000
General and administrative	10,081,000		3,503,000		22,058,000		9,916,000
Intangible asset amortization	2,525,000		706,000		5,340,000		2,100,000
Acquisition costs	345,000		179,000		1,616,000		417,000
Change in fair value of contingent consideration	(140,000)		(2,000)		1,086,000		(1,528,000)
Total operating expenses	44,959,000		12,525,000		98,546,000		34,193,000
Operating loss	(11,159,000)		(1,246,000)		(16,695,000)		(832,000)
Other income (expense):
Change in fair value of warrant liability	0		(1,005,000)		(121,000)		4,467,000
Change in fair value of investments	0		1,110,000		0		1,110,000
Interest (expense) income, net	(194,000)		13,000		(331,000)		59,000
Other expense	(7,000)		(5,000)		(7,000)		(9,000)
Gain on acquisition of Sexton Biotechnologies, Inc.	6,451,000		0		6,451,000		0
Total other income, net	6,250,000		113,000		5,992,000		5,627,000
(Loss) income before income tax benefit	(4,909,000)		(1,133,000)		(10,703,000)		4,795,000
Income tax benefit	4,988,000		0		17,540,000		0
Net income (loss)	79,000		(1,133,000)		6,837,000		4,795,000
Net income (loss) attributable to common shareholders:
Basic	77,000		(1,133,000)		6,621,000		4,322,000
Diluted	$ 77,000		$ (1,133,000)		$ 6,628,000		$ 279,000
Basic (in dollars per share)	$ 0		$ (0.04)		$ 0.18		$ 0.17
Diluted (in dollars per share)	$ 0		$ (0.04)		$ 0.17		$ 0.01
Weighted average shares used to compute earnings (loss) per share attributable to common shareholders:
Basic (in shares)	40,911,801		31,639,420		37,435,224		25,418,375
Diluted (in shares)	43,296,470		31,639,420		39,984,923		29,412,538
Product [Member]
Revenue	$ 29,201,000		$ 10,804,000		$ 70,445,000		$ 32,020,000
Costs and operating expenses:
Cost of goods and services	21,672,000		4,402,000		43,280,000		12,938,000
Service Revenue [Member]
Revenue	2,250,000		0		6,417,000		0
Costs and operating expenses:
Cost of goods and services	1,768,000		0		4,548,000		0
Rental Revenue [Member]
Revenue	2,349,000		475,000		4,989,000		1,341,000
Costs and operating expenses:
Cost of goods and services	$ 1,424,000		$ 424,000		$ 3,140,000		$ 955,000
[1]	2020 revenue includes service revenue related to SciSafe from October 1, 2020 through December 31, 2020.
[2]	2019 revenue includes automated thawing revenue related to Astero from April 1, 2019 through December 31, 2019; evo shipper rental revenue related to SAVSU from August 8, 2019 through December 31, 2019; and freezer and accessory revenue related to CBS from November 12, 2019 through December 31, 2019.

Unaudited Condensed Consolida_4

Unaudited Condensed Consolidated Statements of Comprehensive Income (Loss) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Net income	$ 79	$ (1,133)	$ 6,837	$ 4,795
Other comprehensive loss	(166)	0	(163)	0
Comprehensive (loss) income	$ (87)	$ (1,133)	$ 6,674	$ 4,795

Unaudited Condensed Consolida_5

Unaudited Condensed Consolidated Statements of Shareholders' Equity - USD ($) $ in Thousands	GCI Acquisition [Member]Common Stock [Member]	GCI Acquisition [Member]Additional Paid-in Capital [Member]	GCI Acquisition [Member]	Sexton Acquisition [Member]Common Stock [Member]	Sexton Acquisition [Member]Additional Paid-in Capital [Member]	Sexton Acquisition [Member]	Preferred Stock [Member]Series A Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	AOCI Attributable to Parent [Member]	Retained Earnings [Member]	Total
Balance (in shares) at Dec. 31, 2019							0	20,825,452
Balance at Dec. 31, 2019							$ 0	$ 21	$ 143,485		$ (100,052)	$ 43,454
Stock based compensation									3,818			3,818
Stock option exercises (in shares)								528,793
Stock option exercises									1,028			1,028
Cashless exercises of warrants (in shares)								2,747,970
Cashless exercises of warrants								$ 3	33,108			33,111
Stock issued – on vested RSAs (in shares)							0	161,263
Net income (loss)											4,795	4,795
Stock issued as 2019 bonus payout									314			314
Sale of common stock, net of fees (in shares)								7,856,012
Sale of common stock, net of fees								$ 8	100,113			100,121
Common stock issued for services (in shares)								3,175
Common stock issued for services									60			60
Warrant exercises (in shares)								8,500
Warrant exercises									150			150
Balance (in shares) at Sep. 30, 2020								32,131,165
Balance at Sep. 30, 2020								$ 32	282,076	$ 0	(95,257)	186,851
Balance (in shares) at Jun. 30, 2020								25,982,367
Balance at Jun. 30, 2020								$ 26	199,941		(94,124)	105,843
Stock based compensation									1,560			1,560
Stock option exercises (in shares)								118,000
Stock option exercises									244			244
Stock issued – on vested RSAs (in shares)							0	72,873
Net income (loss)											(1,133)	(1,133)
Sale of common stock, net of fees (in shares)								5,951,250
Sale of common stock, net of fees								$ 6	80,201			80,207
Common stock issued for services (in shares)								3,175
Common stock issued for services									60			60
Warrant exercises (in shares)								3,500
Warrant exercises									70			70
Balance (in shares) at Sep. 30, 2020								32,131,165
Balance at Sep. 30, 2020								$ 32	282,076	0	(95,257)	186,851
Balance (in shares) at Dec. 31, 2020								33,039,146
Balance at Dec. 31, 2020								$ 33	302,598	0	(97,385)	205,246
Stock issued as consideration in GCI acquisition (in shares)	6,636,470			530,502
Stock issued as consideration in GCI acquisition	$ 7	$ 232,734	$ 232,741		$ 31,977	$ 31,977
Fees incurred for registration filings									(188)			(188)
Stock based compensation									8,891			8,891
Stock option exercises (in shares)								632,665
Stock option exercises								$ 1	1,016			1,017
Cashless exercises of warrants (in shares)								70,030
Cashless exercises of warrants									2,901			2,901
Stock issued – on vested RSAs (in shares)							0	535,378
Foreign currency translation										(163)		(163)
Net income (loss)											6,837	6,837
Balance (in shares) at Sep. 30, 2021								41,444,191
Balance at Sep. 30, 2021								$ 41	579,929	(163)	(90,548)	489,259
Balance (in shares) at Jun. 30, 2021								40,560,720
Balance at Jun. 30, 2021								$ 41	542,864	3	(90,627)	452,281
Stock issued as consideration in GCI acquisition (in shares)				530,502
Stock issued as consideration in GCI acquisition					$ 31,977	$ 31,977
Fees incurred for registration filings									(188)			(188)
Stock based compensation									4,868			4,868
Stock option exercises (in shares)								244,906
Stock option exercises									408			408
Stock issued – on vested RSAs (in shares)							0	108,063
Foreign currency translation										(166)		(166)
Net income (loss)							$ 0	$ 0	0	0	79	79
Balance (in shares) at Sep. 30, 2021								41,444,191
Balance at Sep. 30, 2021								$ 41	$ 579,929	$ (163)	$ (90,548)	$ 489,259

Unaudited Condensed Consolida_6

Unaudited Condensed Consolidated Statements of Shareholders' Equity (Parentheticals) - shares	May 14, 2020	Sep. 30, 2021	Sep. 30, 2020
WAVI Holding AG and Taurus4757 GmbH Warrants [Member]
Cashless warrant exercises (in shares)	3,871,405	79,100	3,871,405
Cashless warrant exercises (in shares)		79,100

Unaudited Condensed Consolida_7

Unaudited Condensed Consolidated Statements of Cash Flows - USD ($)	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Cash flows from operating activities
Net income	$ 6,837,000	$ 4,795,000
Adjustments to reconcile net income to net cash (used in) provided by operating activities
Depreciation	3,035,000	1,454,000
Amortization of intangible assets	5,340,000	2,100,000
Stock-based compensation	8,891,000	3,818,000
Non-cash lease expense	1,795,000	455,000
Deferred income tax benefit	(17,540,000)	0
Change in fair value of contingent consideration	1,086,000	(1,528,000)
Change in fair value of warrant liability	121,000	(4,467,000)
Change in fair value of investments	0	(1,110,000)
Gain on acquisition of Sexton Biotechnologies, Inc.	(6,451,000)	0
Stock issued for services	0	30,000
Loss on disposal of assets held for rent, net	333,000	0
Other	504,000	9,000
Change in operating assets and liabilities, net of effects of acquisitions
Accounts receivable, trade, net	(7,140,000)	(820,000)
Inventories	(1,237,000)	(65,000)
Prepaid expenses and other current assets	1,769,000	68,000
Accounts payable	1,368,000	(604,000)
Accrued expenses and other current liabilities	(2,530,000)	689,000
Other	0	(436,000)
Net cash (used in) provided by operating activities	(3,819,000)	4,388,000
Cash flows from investing activities
Cash acquired in acquisition of Global Cooling, Inc. and Sexton Biotechnologies, Inc.	1,559,000
Payments related to the acquisition of SciSafe, net of cash acquired		(500,000)
Purchases of property and equipment	(6,819,000)	(370,000)
Purchases of assets held for lease	(5,412,000)	(1,791,000)
Proceeds from sale of equipment	22,000	3,000
Net cash used in investing activities	(10,650,000)	(2,658,000)
Cash flows from financing activities
Payments of contingent consideration	0	(483,000)
Proceeds from sale of common stock, net of $6.2 million of costs in 2020	0	100,251,000
Fees paid related to issuance of common stock	(145,000)	(6,200,000)
Proceeds from line of credit	26,450,000	0
Payments on line of credit	(28,657,000)	0
Proceeds from exercise of common stock options	1,017,000	1,028,000
Proceeds from exercise of warrants	0	40,000
Other	(280,000)	(30,000)
Net cash (used in) provided by financing activities	(673,000)	100,806,000
Net (decrease) increase in cash, cash equivalents, and restricted cash	(15,142,000)	102,536,000
Cash, cash equivalents, and restricted cash – beginning of period	90,456,000	6,448,000
Effects of currency translation on cash, cash equivalents, and restricted cash	(163,000)	0
Cash, cash equivalents, and restricted cash – end of period	75,151,000	108,984,000
Non-cash investing and financing activities
Cashless exercise of warrants reclassified from warrant liability to common stock	2,901,000	33,111,000
Value of issued shares	264,718,000	0
Equipment acquired under operating leases	6,971,000	0
Equipment acquired under finance leases	440,000	0
Purchase of property and equipment not yet paid	305,000	29,000
Reclassification of warrant liabilities to equity upon exercise	0	110,000
Financing costs paid in a prior period	0	130,000
Stock issued as a prepayment of services	0	30,000
Purchase of equipment with debt	0	270,000
Bonus Consideration [Member]
Non-cash investing and financing activities
Stock issued as a prepayment of services	0	314,000
Paycheck Protection Program CARES Act [Member]
Cash flows from financing activities
Proceeds from Loan	0	2,175,000
Payoff of PPP Loan	0	(2,175,000)
Equipment Loans [Member]
Cash flows from financing activities
Proceeds from Loan	1,640,000	0
Financed Insurance Premium [Member]
Cash flows from financing activities
Payments on financed insurance premium	$ (698,000)	$ 0

Unaudited Condensed Consolida_8

Unaudited Condensed Consolidated Statements of Cash Flows (Parentheticals) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Stock issuance costs	$ 145	$ 6,200

Note 1 - Organization and Signi

Note 1 - Organization and Significant Accounting Policies	9 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Basis of Presentation and Significant Accounting Policies [Text Block]	1. Business BioLife Solutions, Inc. (“BioLife”, “us”, “we”, “our”, or the “Company”) is a developer, manufacturer, and supplier of a portfolio of bioproduction tools and services including proprietary biopreservation media, automated thawing devices, cloud-connected shipping containers, ultra-low temperature mechanical freezers, cryogenic and controlled rate freezers and biological and pharmaceutical materials storage. Our CryoStor® freeze media and HypoThermosol® hypothermic storage media are optimized to preserve cells in the regenerative medicine market. These novel biopreservation media products are serum-free and protein-free, fully defined, and are formulated to reduce preservation-induced cell damage and death. Our Sexton cell processing product line includes human platelet lysates (“hPL”) for cell expansion reducing risk and improving downstream performance over fetal bovine serum, human serum, and other chemically defined media, CellSeal® cryogenic vials that are purpose-built rigid containers used in cell and gene therapy (“CGT”) that can be filled manually or with high throughput systems, and automated cell processing machines that bring multiple processes traditionally performed by manual techniques under a higher level of control to protect therapies from loss or contamination. Our ThawSTAR® product line is comprised of a family of automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags. These products administer temperature-sensitive biologic therapies to patients by standardizing the thawing process and reducing the risks of contamination and overheating, which are inherent with the use of traditional water baths. Our cryogenic freezer technology provides for controlled rate freezing and storage of biologic materials. Our ultra-low temperature mechanical freezers allow biological materials and vaccines to be stored at temperatures which range from negative 20℃ 80℃. Use of estimates The preparation of financial statements in conformity with generally accepted accounting principles in the United States (“U.S. GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities as of the date of the financial statements and reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates and assumptions by management affect the Company’s allowance for doubtful accounts, the net realizable value of inventory, fair value of warrant liability, valuation of market based awards, valuations and purchase price allocations related to investments and business combinations, expected future cash flows including growth rates, discount rates, terminal values and other assumptions and estimates used to evaluate the recoverability of long-lived assets, estimated fair values of intangible assets and goodwill, amortization methods and periods, certain accrued expenses, share-based compensation, contingent consideration from business combinations, tax reserves, and the recoverability of the Company’s net deferred tax assets and the related valuation allowance. The Company regularly assesses these estimates; however, actual results could differ materially from these estimates. Changes in estimates are recorded in the period in which they become known. The Company bases its estimates on historical experience and various other assumptions that it believes to be reasonable under the circumstances. Basis of presentation The Unaudited Condensed Consolidated Financial Statements included herein have been prepared by BioLife in accordance with U.S. GAAP and pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”), for Quarterly Reports on Form 10 10 X not 10 December 31, 2020. The Unaudited Condensed Consolidated Financial Statements include the accounts of the Company and its wholly-owned subsidiaries, Astero Bio Corporation (“Astero,” and the Astero product line, “ThawStar” acquired on April 1, 2019), August 8, 2019), November 12, 2019), October 1, 2020), May 3, 2021), September 1, 2021). In the opinion of management, the accompanying Unaudited Condensed Consolidated Financial Statements include all adjustments, consisting of only normal, recurring adjustments necessary for a fair presentation of the financial position, results of operations, and cash flows. The results of operations for the interim periods presented are not Financial Statement Reclassification Certain classifications on the Unaudited Condensed Consolidated Balance Sheets related to accrued expenses and other current liabilities, debt, current portion, and debt, long-term as of December 31, 2020 no Segment reporting The Company operates and manages its business as one Significant accounting policies There have been no nine September 30, 2021, 10 Liquidity and capital resources On September 30, 2021 December 31, 2020, may may not Risks and uncertainties On March 10, 2020, 2, 2019 19” 19 19, 19. not 19, The Company may 19 third Any disruption and volatility in the global capital markets as a result of the pandemic may 19 not The ultimate extent to which the COVID- 19 19 On March 27, 2020, As of March 30, 2020, September 30, 2021, 2021 2022. On March 11, 2021, 2021” In the SciSafe acquisition, the Company assumed a $295,300 loan from the PPP. The loan incurs interest at 1% and is unsecured. Should any portion of the principal of the note not October 2022. no Concentrations of credit risk and business risk We derived approximately 19% and 14% of revenue from one three nine September 30, 2021, one three nine September 30, 2020, No 10% three nine September 30, 2021 2020. The following table represents the Company’s total revenue by geographic area (based on the location of the customer): Three Months Ended Nine Months Ended September 30, September 30, Revenue by customers geographic locations 2021 2020 2021 2020 North America 88 % 84 % 87 % 86 % Europe, Middle East, Africa (EMEA) 9 % 13 % 10 % 12 % Other 3 % 3 % 3 % 2 % Total revenue 100 % 100 % 100 % 100 % We derived approximately 30% and 33% of our revenue from CryoStor products in the three nine September 30, 2021, three nine September 30, 2020. 780XLE three nine September 30, 2021, 780XLE not 10% three nine September 30, 2020. As of September 30, 2021 December 31, 2020, two one No 10% September 30, 2021 December 31, 2020. As of September 30, 2021 December 31, 2020, one No 10% September 30, 2021 December 31, 2020. Recent accounting pronouncements In October 2021, 2021 08, 805 Accounting for Contract Assets and Contract Liabilities from Contracts with Customers 606 606 2021 08 December 15, 2022, In July 2021, 2021 05, 842 Lessors - Certain Leases with Variable Lease Payments 2021 05" 2021 05 840. not 1 842 10 25 2 25 3; 2 one 2021 05 December 15, 2021, 2021 05 In May 2021, No. 2021 04, Issuer s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options 2021 04 2021 04 December 15, 2021, 2021 04 not not In August 2020, No. 2020 06, Debt - Debt with Conversion and Other Options (Subtopic 470 20 s Own Equity (Subtopic 815 40 2020 06 2020 06 2020 06 December 15, 2021, no December 15, 2020. not In March 2020, No. 2020 04, Reference Rate Reform (Topic 848 January 2021, 2021 01, no December 1, 2022, not In June 2016, No. 2016 13, Financial Instruments Credit Losses (Topic 326 2016 13 2016 13 December 15, 2023,

Note 2 - Fair Value Measurement

Note 2 - Fair Value Measurement	9 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Fair Value Disclosures [Text Block]	2. Fair value measurement In accordance with FASB ASC Topic 820, Fair Value Measurements and Disclosures 820” 820 820 three Level 1 Level 2 1 not Level 3 The fair value of the Astero Contingent Consideration liability was initially valued based on unobservable inputs using a Black-Scholes valuation model. These inputs included the estimated amount and timing of projected future revenue, a discount rate of 17.5%, risk-free rates between 2.29% and 2.41% and revenue volatility of 56%. Significant increases (decreases) in any of those inputs in isolation would result in a significantly higher (lower) fair value measurement. Generally, changes used in the assumptions for projected future revenue and revenue volatility would be accompanied by a directionally similar change in the fair value measurement. Conversely, changes in the discount rate would be accompanied by a directionally opposite change in the related fair value measurement. However, due to the Contingent Consideration having a maximum payout amount, changes in these assumptions would not September 30, 2021, three nine September 30, 2021, December 31, 2020 $81,000. may The fair value of the CBS Contingent Consideration liability was initially valued based on unobservable inputs using a Monte Carlo simulation. These inputs included the estimated amount and timing of projected future revenue, a discount rate of 26.0%, a risk-free rate of approximately 1.74% and revenue volatility of 70%. Significant increases (decreases) in any of those inputs in isolation would result in a significantly higher (lower) fair value measurement. Generally, changes used in the assumptions for projected future revenue and revenue volatility would be accompanied by a directionally similar change in the fair value measurement. Conversely, changes in the discount rate would be accompanied by a directionally opposite change in the related fair value measurement. However, due to the Contingent Consideration having a maximum payout amount, changes in these assumptions would not September 30, 2021, September 30, 2021 December 31, 2020 may The fair value of the SciSafe Contingent Consideration liability was initially valued based on unobservable inputs using a Monte Carlo simulation. These inputs included the estimated amount and timing of projected future revenue, a discount rate of 4.5%, a risk-free rate of approximately 0.20%, asset volatility of 60%, and revenue volatility of 15%. Significant increases (decreases) in any of those inputs in isolation would result in a significantly higher (lower) fair value measurement. Generally, changes used in the assumptions for projected future revenue and revenue volatility would be accompanied by a directionally similar change in the fair value measurement. Conversely, changes in the discount rate would be accompanied by a directionally opposite change in the related fair value measurement. However, due to the Contingent Consideration having a maximum payout amount, changes in these assumptions would not September 30, 2021, September 30, 2021 December 31, 2020 three nine September 30, 2021, may For the warrant liability, the significant Level 3 March 25, 2021. December 31, 2020, not March 25, 2021, There were no nine September 30, 2021 not The following tables set forth the Company’s financial assets measured at fair value on a recurring basis as of September 30, 2021 December 31, 2020, three (In thousands) As of September 30, 2021 Level 1 Level 2 Level 3 Total Assets: Money market accounts $ 70,152 $ - $ - $ 70,152 Total 70,152 - - 70,152 Liabilities: Contingent consideration - business combinations - - 8,238 8,238 Total $ - $ - $ 8,238 $ 8,238 As of December 31, 2020 Level 1 Level 2 Level 3 Total Assets: Money market accounts $ 90,403 $ - $ - $ 90,403 Total 90,403 - - 90,403 Liabilities: Contingent consideration - business combinations - - 7,152 7,152 Warrant liability - - 2,780 2,780 Total $ - $ - $ 9,932 $ 9,932 The fair values of money market funds classified as Level 1 3 no The following table presents the changes in fair value of contingent consideration liabilities which are measured using Level 3 Nine Months Ended September 30, (In thousands) 2021 2020 Beginning balance $ 7,152 $ 1,914 Change in fair value recognized in net income (loss) 1,086 (1,528 ) Ending balance $ 8,238 $ 386 The following table presents the changes in fair value of warrant liabilities which are measured using Level 3 Nine Months Ended September 30, (In thousands) 2021 2020 Beginning balance $ 2,780 $ 39,602 Exercised warrants (2,901 ) (33,221 ) Change in fair value recognized in net income (loss) 121 (4,467 ) Ending balance $ - $ 1,914

Note 3 - Acquisitions

Note 3 - Acquisitions	9 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Business Combination Disclosure [Text Block]	3. Sexton acquisition General terms and effects On August 9, 2021, On September 1, 2021, three nine September 30, 2021. Total consideration transferred (in thousands, except number of shares and stock price): Merger consideration shares 530,502 BioLife stock price (as of September 1, 2021) $ 60.50 Value of issued shares $ 32,095 plus: Fair value of BioLife’s existing investment in Sexton $ 7,951 less: Net working capital adjustment $ (118 ) Merger Consideration $ 39,928 Transaction costs related to the acquisition are expensed as incurred and are not Fair value of net assets acquired As the Company finalizes its estimation of the fair value of the assets acquired and liabilities assumed, additional adjustments may not 12 September 30, 2021 Under the acquisition method of accounting, the assets acquired and liabilities assumed from Sexton were estimated as of the merger date, at their respective fair values, and consolidated with those of BioLife. The estimated fair value of the net tangible assets acquired is approximately $4.1 million, the estimated fair value of the deferred tax liability acquired is approximately $1.3 million, the estimated fair value of the intangible assets acquired is approximately $8.8 million, and the estimated residual goodwill is approximately $28.3 million. The gross contractual accounts receivable acquired in the acquisition was $509,000. Of the acquired accounts receivable, $17,000 is estimated to be uncollectable. The fair value calculations required critical estimates, including, but not The table below represents the estimated fair value of the net assets acquired and liabilities assumed, which were recorded as of the merger date (amounts in thousands). Cash $ 1,516 Accounts receivable, net 492 Inventory 1,310 Prepaid expenses and other current assets 670 Property, plant and equipment, net 737 Operating lease right-of-use assets, net 470 Developed technology 4,132 Customer relationships 2,276 Tradenames 2,324 Non-compete agreements 90 Goodwill 28,273 Accounts payable (291 ) Lease liabilities, operating (470 ) Deferred tax liability (1,284 ) Other liabilities (317 ) Fair value of net assets acquired $ 39,928 The fair value of Sexton’s identifiable intangible assets and useful lives are as follows (amounts in thousands, except years): Fair Value Useful Life (Years) Developed technology $ 4,132 5 - 9 Customer relationships 2,276 2 Tradenames 2,324 11 Non-compete agreements 90 1 Total identifiable intangible assets $ 8,822 Fair value measurement methodologies used to calculate the value of any asset can be broadly classified into one three three not Some of the more significant assumptions inherent in the development of intangible asset fair values, from the perspective of a market participant, include, but are not Acquired goodwill The goodwill of $28.3 not Global Cooling acquisition General terms and effects On March 19, 2021, On May 3, 2021, Merger consideration The aggregate merger consideration paid pursuant to the GCI Merger Agreement to the GCI Stockholders was 6,646,870 newly issued shares of common stock, provided, however, that the GCI Merger Consideration otherwise payable to GCI Stockholders is subject to the withholding of the GCI Escrow Shares (as defined below) and is subject to reduction for indemnification obligations. The GCI Merger Consideration allocable to one 805, not Total consideration transferred (in thousands, except number of shares, stock price, and consideration percentage): BioLife shares outstanding (as of March 19, 2021) 33,401,359 Merger consideration percentage 19.9 % Merger consideration shares 6,646,870 less: Merger consideration shares withheld to satisfy outstanding GCI stockholder obligations to GCI 10,400 Subtotal 6,636,470 BioLife stock price (as of May 3, 2021) $ 35.07 Value of issued shares $ 232,741 plus: Settlement of BioLife prepaid deposits $ 2,152 plus: Net settlement of BioLife accounts receivable $ 16 Merger Consideration $ 234,909 Transaction costs related to the acquisition are expensed as incurred and are not Escrow shares At the GCI Closing, approximately nine The GCI Escrow Property will be held for a period of up to twenty-four Fair value of net assets acquired As the Company finalizes its estimation of the fair value of the assets acquired and liabilities assumed, additional adjustments may not 12 September 30, 2021 may Under the acquisition method of accounting, the assets acquired and liabilities assumed from Global Cooling were estimated as of the merger date, at their respective fair values, and consolidated with those of BioLife. The estimated fair value of the net tangible assets acquired is approximately $740,000, the estimated fair value of the deferred tax liability acquired is approximately $23.5 million, the estimated fair value of the intangible assets acquired is approximately $120.5 million, and the estimated residual goodwill is approximately $137.2 million. The gross contractual accounts receivable acquired in the acquisition was $7.1 million. Of the acquired accounts receivable, $53,000 was estimated to be uncollectable. The fair value calculations required critical estimates, including, but not The table below represents the estimated fair value of the net assets acquired and liabilities assumed, which were recorded as of the merger date (amounts in thousands). Cash $ 43 Accounts receivable, net 7,076 Inventory 15,547 Prepaid expenses and other current assets 639 Property, plant and equipment, net 3,512 Operating lease right-of-use assets, net 1,741 Financing lease right-of-use assets, net 114 Long-term deposits and other assets 4 Developed technology 18,140 Customer relationships 7,020 Tradenames 26,640 Non-compete agreements 1,240 In-process research and development 67,440 Goodwill 137,215 Accounts payable (9,837 ) Line of credit (4,231 ) Lease liabilities, operating (1,880 ) Lease liabilities, financing (114 ) Long-term debt (4,410 ) Deferred tax liability (23,526 ) Other liabilities (7,464 ) Fair value of net assets acquired $ 234,909 The fair value of Global Cooling’s identifiable intangible assets and useful lives are as follows (amounts in thousands, except years): Fair Value Useful Life (Years) Developed technology $ 18,140 6 Customer relationships 7,020 12 Tradenames 26,640 15 Non-compete agreements 1,240 4 In-process research and development 67,440 N/A Total identifiable intangible assets $ 120,480 Fair value measurement methodologies used to calculate the value of any asset can be broadly classified into one three three not Some of the more significant assumptions inherent in the development of intangible asset fair values, from the perspective of a market participant, include, but are not Acquired goodwill The goodwill of $137.2 million represents future economic benefits expected to arise from synergies from combining operations and commercial organizations to increase market presence and the extension of existing customer relationships. The goodwill recorded is not The Company recorded revenue from Sexton of $425,000 and a net loss of $227,000 from September 1, 2021, September 30, 2021. May 3, 2021, September 30, 2021. The following unaudited pro forma financial information presents the combined results of operations of Sexton as if the acquisition had occurred on January 1, 2020 Three Months Ended Nine Months Ended September 30, September 30, (In thousands) 2021 (unaudited) 2020 (unaudited) 2021 (unaudited) 2020 (unaudited) Total revenue $ 34,524 $ 11,697 $ 85,189 $ 34,707 Net (loss) income $ (685 ) $ (1,850 ) $ 4,612 $ 2,056 The following unaudited pro forma financial information presents the combined results of operations of Global Cooling as if the acquisition had occurred on January 1, 2020 Three Months Ended Nine Months Ended September 30, September 30, (In thousands) 2021 (unaudited) 2020 (unaudited) 2021 (unaudited) 2020 (unaudited) Total revenue $ 33,800 $ 21,204 $ 106,427 $ 58,056 Net income (loss) $ 79 $ (3,393 ) $ (1,939 ) $ 4,912

Note 4 - Inventory

Note 4 - Inventory	9 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Inventory Disclosure [Text Block]	4. Inventory consists of the following as of September 30, 2021 December 31, 2020: (In thousands) 2021 2020 Raw materials $ 16,445 $ 2,855 Work in progress 4,597 2,006 Finished goods 8,654 6,741 Total $ 29,696 $ 11,602

Note 5 - Assets Held for Rent

Note 5 - Assets Held for Rent	9 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Assets Held For Rent [Text Block]	5. Assets held for rent Assets held for rent consist of the following as of September 30, 2021 December 31, 2020: (In thousands) 2021 2020 Shippers placed in service $ 5,433 $ 3,171 Fixed assets held for rent 3,603 - Accumulated depreciation (1,284 ) (411 ) Net 7,752 2,760 Shippers and related components in production 2,334 1,945 Total $ 10,086 $ 4,705 Shippers and related components in production include shippers complete and ready to be deployed and placed in service upon a customer order, shippers in the process of being assembled, and components available to build shippers. We recognized $410,000 and $873,000 in depreciation expense related to assets held for rent during the three nine September 30, 2021, three nine September 30, 2020,

Note 6 - Goodwill and Intangibl

Note 6 - Goodwill and Intangible Assets	9 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Goodwill and Intangible Assets Disclosure [Text Block]	6. Goodwill Goodwill represents the difference between the purchase price and the estimated fair value of identifiable assets acquired and liabilities assumed. Goodwill acquired in a business combination is determined to have an indefinite useful life and is not 350. not nine September 30, 2021. Intangible assets Intangible assets, net consisted of the following as of September 30, 2021: (In thousands, except weighted average useful life) September 30, 2021 Finite-lived intangible assets: Gross Carrying Value Accumulated Amortization Net Carrying Value Weighted Average Usefu l Life (in years) Customer Relationships $ 17,516 $ (1,177 ) $ 16,339 10.8 Tradenames 35,574 (1,672 ) 33,902 14.4 Technology - acquired 41,942 (6,300 ) 35,642 6.1 Non-compete agreements 1,990 (302 ) 1,688 3.3 In-process research and development⁽¹⁾ 67,440 - 67,440 N/A Total intangible assets $ 164,462 $ (9,451 ) $ 155,011 10.1 ( 1 not Intangible assets, net consisted of the following as of December 31, 2020: December 31, 2020 Finite-lived intangible assets: Gross Carrying Value Accumulated Amortization Net Carrying Value Weighted Average Useful Life (in years) Customer Relationships $ 8,220 $ (330 ) $ 7,890 12.8 Tradenames 6,610 (508 ) 6,102 14.0 Technology - acquired 19,670 (3,232 ) 16,438 7.1 Non-compete agreements 660 (41 ) 619 3.8 Total intangible assets $ 35,160 $ (4,111 ) $ 31,049 9.7 Amortization expense for finite-lived intangible assets was $2.5 million and $5.3 million for the three nine September 30, 2021, three nine September 30, 2020, September 30, 2021, (In thousands) For the Years Ending December 31, Estimated Amortization Expense 2021 (3 months remaining) $ 2,858 2022 11,403 2023 10,934 2024 10,109 2025 9,730 Thereafter 42,537 Total $ 87,571

Note 7 - Line of Credit and Lon

Note 7 - Line of Credit and Long-term Debt	9 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Long-term Debt [Text Block]	7. At September 30, 2021 June 2023. 3 October 14, 2021, Long-term debt consisted of the following as of September 30, 2021 December 31, 2020: September 30, December 31, (In thousands) Maturity Date Interest Rate 2021 2020 2019 term loan Sep-23 10.5 % $ 1,750 $ - 2018 term loan Sep-23 10.5 % 2,813 - Insurance premium financing Apr-22 4.0 % 726 - Paycheck Protection Program loan May-22 1.0 % 295 295 Freezer equipment loan Dec-25 5.7 % 652 365 Manufacturing equipment loans Oct-25 5.7 % 376 439 Freezer installation loan Various 6.3 % 1,395 156 Other loans Various Various 10 14 Total debt 8,017 1,269 Less: Unamortized debt issuance costs (124 ) - Total debt, net of unamortized debt issuance costs $ 7,893 $ 1,269 The 2019 2018 As of September 30, 2021, five (In thousands) Amount 2021 (3 months remaining) $ 950 2022 1,208 2023 2,038 2024 1,944 2025 543 Thereafter 1,334 Total $ 8,017 Debt covenants and default provisions The line of credit, 2019 2018 September 30, 2021, not October 14, 2021. 2019 2018 On October 1, 2021, two one December 7, 2018 October 1, 2019, December 18, 2027 September 7, 2024, one

Note 8 - Share-based Compensati

Note 8 - Share-based Compensation	9 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Share-based Payment Arrangement [Text Block]	8. Share-based compensation Service vesting-based stock options The following is a summary of service vesting based stock option activity for the nine September 30, 2021, September 30, 2021: Nine Months Ended September 30, 2021 Shares Wtd. Avg. Exercise Price Outstanding as of beginning of year 844,455 $ 2.00 Exercised (131,590 ) 1.48 Forfeited (1,146 ) 5.69 Expired (35,714 ) 1.73 Outstanding as of September 30, 2021 676,005 $ 2.12 Stock options exercisable as of September 30, 2021 671,964 $ 2.11 We recognized $6,000 and $21,000 in stock compensation expense related to service vesting-based options during the three nine September 30, 2021, three nine September 30, 2020, September 30, 2021, September 30, 2021. three nine September 30, 2021, three nine September 30, 2020, September 30, 2021 September 30, 2021, Performance-based stock options The following is a summary of performance-based stock option activity under our stock option plan for the nine September 30, 2021, September 30, 2021: Nine Months Ended September 30, 2021 Shares Wtd. Avg. Exercise Price Outstanding as of beginning of year 686,001 $ 1.64 Exercised (501,075 ) 1.64 Outstanding as of September 30, 2021 184,926 $ 1.64 Stock options exercisable as of September 30, 2021 184,926 $ 1.64 No stock compensation expense was recognized during the three nine September 30, 2021 2020 September 30, 2021, September 30, 2021. three nine September 30, 2021, three nine September 30, 2020, September 30, 2021 September 30, 2021 There were no stock options granted to employees and non-employee directors in the three nine September 30, 2021 2020. Restricted stock Service vesting-based restricted stock The following is a summary of service vesting-based restricted stock activity for the nine September 30, 2021, September 30, 2021: Nine Months Ended September 30, 2021 Shares Wtd. Avg. Grant Date Fair Value Outstanding as of beginning of year 930,854 $ 19.31 Granted 751,363 47.50 Vested (241,590 ) 15.97 Forfeited (79,079 ) 34.86 Non-vested as of September 30, 2021 1,361,548 $ 34.56 The aggregate fair value of the service vesting-based awards granted was $31.1 million and $35.7 million during the three nine September 30, 2021, three nine September 30, 2020 three nine September 30, 2021, three nine September 30, 2020, We recognized $4.4 million and $8.0 million in stock compensation expense related to service vesting-based restricted stock awards during the three nine September 30, 2021, three nine September 30, 2020, September 30, 2021, Performance-based restricted stock We recognized stock compensation benefit of $0 and $186,000 for the three nine September 30, 2021 not three nine September 30, 2020, September 30, 2021, Market-based restricted stock The following is a summary of market-based restricted stock option activity under our stock option plan for the nine September 30, 2021 September 30, 2021: Nine Months Ended September 30, 2021 Shares Wtd. Avg. Grant Date Fair Value Outstanding as of beginning of year 224,774 $ 19.20 Granted 152,665 30.85 Vested (231,268 ) 26.98 Non-vested as of September 30, 2021 146,171 $ 20.78 On February 25, 2019, April 1, 2019 February 8, 2021, January 1, 2019 December 31, 2020 20 2 0% December 31, 2020. On March 25, 2020, January 1, 2020 December 31, 2021 20 2 0% 2 December 31, 2021. On February 8, 2021, January 1, 2021 December 31, 2022 20 0% December 31, 2022. On May 3, 2021, one January 1, 2021 December 31, 2022 20 0% December 31, 2022. We recognized $413,000 and $1.1 million in stock compensation expense related to market-based restricted stock awards during the three nine September 30, 2021, three nine September 30, 2020, September 30, 2021, We recorded total stock compensation expense for the three nine September 30, 2021 2020, Three Months Ended Nine Months Ended September 30, September 30, 2021 2020 2021 2020 Research and development costs $ 551 $ 291 $ 1,171 $ 687 Sales and marketing costs 560 256 1,012 581 General and administrative costs 3,015 868 5,662 2,144 Cost of revenue 742 145 1,047 406 Total $ 4,868 $ 1,560 $ 8,892 $ 3,818

Note 9 - Warrants

Note 9 - Warrants	9 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Warrants [Text Block]	9. In March 2014, March 2021. In May 2016, May 2021. On May 14, 2020, Taurus4757 On March 25, 2021, The following table summarizes warrant activity for the nine September 30, 2021: Shares Wtd. Avg. Exercise Price Outstanding as of December 31, 2020 79,100 $ 4.75 Exercised (79,100 ) 4.75 Outstanding and exercisable as of September 30, 2021 - $ -

Note 10 - Income Taxes

Note 10 - Income Taxes	9 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Income Tax Disclosure [Text Block]	10. The Company accounts for income taxes under ASC Topic 740 The Company’s tax provision for interim periods is determined using an estimate of the annual effective income tax rate, adjusted for discrete items, if any, that occur in the relevant period. The income tax benefit of $17.5 million for the nine September 30, 2021 $17.5 May 3, 2021 The income tax benefit of $5.0 million for the three September 30, 2021 The Company’s US projected effective income tax rate without discrete items was 18%, which is lower than the US federal statutory rate of 21% primarily due to the impact of a projected partial valuation allowance on net operating loss carryforwards, non-deductible transaction costs and executive compensation offset by state tax benefits and research tax credits. Realization of deferred tax assets is dependent upon the generation of future taxable income, the timing and amount of which are uncertain. In determining the need for a valuation allowance, the Company’s management evaluates both positive and negative evidence when concluding whether it is more likely than not In connection with the Global Cooling acquisition on May 3, 2021, August 9, 2021, Future utilization of the net operating loss and tax credit carryforwards may 382 1986, 382, 382 may

Note 11 - Net (Loss) Income Per

Note 11 - Net (Loss) Income Per Common Share	9 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Earnings Per Share [Text Block]	11. The Company considers its unexercised warrants and unvested restricted shares, which contain non-forfeitable rights to dividends, participating securities, and includes such participating securities in its computation of earnings per share pursuant to the two two two The following table presents computations of basic and diluted earnings per share under the two Three Months Ended Nine Months Ended September 30, September 30, (In thousands, except share and earnings per share data) 2021 2020 2021 2020 Basic earnings (loss) per common share Numerator: Net income (loss) $ 79 $ (1,133 ) $ 6,837 $ 4,795 Amount attributable to unvested restricted shares (2 ) - (212 ) (138 ) Amount attributable to warrants outstanding - - (4 ) (335 ) Net income (loss) allocated to common shareholders 77 (1,133 ) 6,621 4,322 Denominator: Weighted-average common shares issued and outstanding 40,911,801 31,639,420 37,435,224 25,418,375 Basic earnings (loss) per common share $ 0.00 $ (0.04 ) $ 0.18 $ 0.17 Diluted earnings (loss) per common share Numerator: Net income (loss) $ 79 $ (1,133 ) $ 6,837 $ 4,795 Amount attributable to unvested restricted shares (2 ) - (205 ) - Amount attributable to warrants - - (4 ) (49 ) Less: gain related to change in fair value of warrants - - - (4,467 ) Diluted earnings (loss) per common share 77 (1,133 ) 6,628 279 Denominator: Weighted-average common shares issued and outstanding 40,911,801 31,639,420 37,435,224 25,418,375 Dilutive potential common shares from: Stock options 1,069,207 - 1,330,207 1,754,051 Restricted shares 1,315,462 - 1,195,154 285,975 Warrants - - 24,338 1,954,137 Diluted weighted average shares issued and outstanding 43,296,470 31,639,420 39,984,923 29,412,538 Diluted earnings (loss) per common share $ 0.00 $ (0.04 ) $ 0.17 $ 0.01 The following table sets forth the number of weighted-average common shares excluded from the computation of diluted loss per share, as their inclusion would have been anti-dilutive: Three Months Ended Nine Months Ended September 30, September 30, 2021 2020 2021 2020 Stock options and restricted stock awards - 2,183,537 - - Warrants - 62,769 - - Total - 2,246,306 - -

Note 12 - Commitments and Conti

Note 12 - Commitments and Contingencies	9 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	12. Employment agreements We have employment agreements with certain key employees. None may Litigation From time to time, the Company is subject to various legal proceedings that arise in the ordinary course of business, none may not Indemnification As permitted under Delaware law and in accordance with the Company’s bylaws, the Company is required to indemnify its officers and directors for certain errors and occurrences while the officer or director is or was serving in such capacity. The Company is also party to indemnification agreements with its directors. The Company believes the fair value of the indemnification rights and agreements is minimal. Accordingly, the Company has not September 30, 2021.

Note 13 - Revenue

Note 13 - Revenue	9 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Revenue from Contract with Customer [Text Block]	13. To determine revenue recognition for contractual arrangements that we determine are within the scope of Financial Accounting Standards Board (“FASB”) Topic 606, Revenue from Contracts with Customers five five The Company also generates revenue from the leasing of our property, plant, and equipment, operating right-of-use assets, and evo cold chain systems to customers pursuant to service contracts or rental arrangements entered into with the customer. Revenue from these arrangements is not 606 842, Leases Total bioproduction tools and services revenue for three nine September 30, 2021 2020 Three Months Ended Nine Months Ended September 30, September 30, (In thousands, except percentages) 2021 2020 2021 2020 Product revenue Freezer and thaw $ 17,610 $ 3,371 $ 40,021 $ 9,237 Cell processing 11,505 7,414 30,131 22,753 Storage and cold chain services 86 19 293 30 Service revenue Storage and cold chain services 2,250 - 6,417 - Rental revenue Storage and cold chain services 2,349 475 4,989 1,341 Total revenue $ 33,800 $ 11,279 $ 81,851 $ 33,361 The following table includes estimated rental revenue expected to be recognized in the future related to embedded leases as well as estimated service revenue expected to be recognized in the future related to performance obligations that are unsatisfied or partially unsatisfied as of the end of the reporting periods. The Company is electing not one 2014 09, Revenue from Contracts with Customers not one September 30, 2021. The balances in the table below are partially based on judgments involved in estimating future orders from customers subject to the exercise of material rights pursuant to respective contracts: Year Ending December 31, (In thousands) 2021 2022 2023 2024 Total Rental revenue $ 2,983 $ 7,733 $ 422 $ - $ 11,138 Service revenue $ 40 $ 31 $ 31 $ 10 $ 112

Note 14 - Leases

Note 14 - Leases	9 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Lessee, Leases [Text Block]	14. Lessee arrangements We lease approximately 32,106 square feet in our Bothell, Washington headquarters. In November 2020, July 31, 2031. 2021 2023. two five first August 1, 2031, second first September 30, 2021, August. We lease approximately 3,460 square feet in our Menlo Park, California location. The term of our lease continues until December 31, 2021. September 30, 2021. We lease approximately 9,932 square feet in our Albuquerque, New Mexico location. The term of our lease continues until December 31, 2021 two three first December 1, 2021, second December 1, 2024. September 30, 2021, We lease approximately 106,998 square feet in our Detroit, Michigan location under a month-to-month arrangement. The monthly base rent is approximately $35,000 as of September 30, 2021. We lease approximately 16,800 square feet in the United States. The term of the lease continues until February 28, 2026 no September 30, 2021, March. We lease approximately 20,000 square feet in the United States. The term of the lease continues until March 31, 2024 no September 30, 2021, April. We lease approximately 12,500 square feet in the United States. The term of the lease continues until January 31, 2023 no September 30, 2021. We lease approximately 16,153 square feet in the United States. The term of the lease continues until June 30, 2024 no September 30, 2021, July. We lease approximately 26,800 square feet in the United States. The term of the lease continues until November 1, 2031 two five first November 1, 2031, second November 1, 2036. September 30, 2021, June, first first first We lease approximately 47,533 square feet in the Netherlands. The term of our lease began on April 1, 2021 March 31, 2026, five €29,000 September 30, 2021) January We lease approximately 50,000 square feet in our Athens, Ohio location. The term of our lease continues until March 31, 2028 September 30, 2021, April. We lease approximately 1,807 square feet in Columbus, Ohio under a month-to-month arrangement. The monthly base rent is approximately $4,000 as of September 30, 2021. We lease approximately 22,764 square feet in Nelsonville, Ohio. The term of the lease continues until May 31, 2022, September 30, 2021. We lease approximately 11,415 square feet in Indianapolis, Indiana. The term of our lease continues until September 30, 2024 one September 30, 2021. Operating leases recorded on our Unaudited Condensed Consolidated Balance Sheets are primarily related to our Bothell, Washington headquarters space lease and our SciSafe space leases in the United States. We have not not not one Our financing leases relate to research equipment, machinery, and other equipment. The table below presents certain information related to the weighted average discount rate and weighted average remaining lease term for the Company’s leases: September 30, December 31, (In thousands) 2021 2020 Weighted average discount rate - operating leases 3.6 % 3.3 % Weighted average discount rate - finance leases 6.1 % 5.7 % Weighted average remaining lease term in years - operating leases 7.9 1.5 Weighted average remaining lease term in years - finance leases 3.2 0.9 Operating cash paid for amounts included in the measurement of operating lease liabilities in the three nine September 30, 2021 three nine September 30, 2020 The components of operating lease expense for the three nine September 30, 2021 Three Months Ended Nine Months Ended September 30, September 30, (In thousands) 2021 2020 2021 2020 Operating lease costs $ 805 $ 170 $ 1,998 $ 509 Short-term lease costs 498 59 1,158 176 Total operating lease costs 1,303 229 3,156 685 Variable lease costs 193 - 477 - Total lease expense $ 1,496 $ 229 $ 3,633 $ 685 Maturities of our operating lease liabilities as of September 30, 2021 (In thousands) Operating Leases Financing Leases 2021 (3 months remaining) $ 890 $ 43 2022 3,108 171 2023 2,760 171 2024 2,523 101 2025 2,245 37 Thereafter 8,780 1 Total lease payments 20,306 524 Less: interest (2,611 ) (49 ) Total present value of lease liabilities $ 17,695 $ 475 Lessor arrangements Rental arrangements The Company generates revenue from the leasing of our evo cold chain systems, which are typically cloud-connected shippers with enabling cold chain cloud applications, to customers pursuant to rental arrangements entered into with the customer. Revenue from the rental of cold chain systems is within the scope of FASB ASC Topic 842, Leases Embedded leases BioLife enters into various customer service agreements (collectively, “Service Contracts”) with customers to provide biological and pharmaceutical storage services. In certain of these Service Contracts, the property, plant, and equipment or operating right-of-use assets used to store the customer product are used only for the benefit of one BioLife has assessed its Service Contracts and concluded that certain of the contracts for the storage of customer products met the criteria to be considered a leasing arrangement (“Embedded Leases”), with BioLife as the lessor. The specific Service Contracts that met the criteria were those that provided a single customer with the ability to substantially direct the use of BioLife property, plant, and equipment or operating right-of-use assets. Under ASC 842, None None

Note 15 - Unaudited Condensed C

Note 15 - Unaudited Condensed Consolidated Balance Sheet Detail	9 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Supplemental Balance Sheet Disclosures [Text Block]	15. Property and equipment September 30, December 31, (In thousands) 2021 2020 Property and equipment Leasehold improvements $ 3,301 $ 2,393 Furniture and computer equipment 1,793 902 Manufacturing and other equipment 13,798 10,076 Construction in-progress 4,747 591 Subtotal 23,639 13,962 Less: Accumulated depreciation (6,177 ) (3,842 ) Net property and equipment $ 17,462 $ 10,120 Depreciation expense for property and equipment was $691,000 and $2.1 million for the three nine September 30, 2021, three nine September 30, 2020, Accrued expenses and other current liabilities Accrued expenses and other current liabilities consist of the following: September 30, December 31, (In thousands) 2021 2020 Accrued expenses $ 1,435 $ 472 Accrued taxes 62 112 Accrued compensation 4,167 2,898 Warranty reserve liability 5,552 212 Deferred revenue, current 710 931 Other 131 130 Total accrued expenses and other current liabilities $ 12,057 $ 4,755 Warranty reserve liability We reserve estimated exposures on known claims, as well as on a portion of anticipated claims, for product warranty and rework cost, based on historical product liability claims. Claim costs are deducted from the accrual when paid. Factors that could have an impact on the warranty accrual in any given period include the following: changes in manufacturing quality, changes in product costs, changes in product mix and any significant changes in sales volume. A rollforward of our warranty liability is as follows: Nine Months Ended September 30, (In thousands) 2021 2020 Beginning balance $ 212 $ 191 Warranty reserve acquired in the acquisition of Global Cooling 3,353 - Provision for warranties 4,446 109 Settlements of warranty claims (2,459 ) (92 ) Ending Balance $ 5,552 $ 208

Note 16 - Employee Benefit Plan

Note 16 - Employee Benefit Plan	9 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Defined Contribution Plan [Text Block]	16. The Company sponsors a 401 may three nine September 30, 2021, three nine September 30, 2020,

Note 17 - Subsequent Events

Note 17 - Subsequent Events	9 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Subsequent Events [Text Block]	17. On October 8, 2021, October 1, 2022 six July 31, 2031. On October 31, 2021, December 31, 2022. January 1, 2022 two one first January 1, 2023, second January 1, 2024.

Significant Accounting Policies

Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2021
Accounting Policies [Abstract]
Use of Estimates, Policy [Policy Text Block]	Use of estimates The preparation of financial statements in conformity with generally accepted accounting principles in the United States (“U.S. GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities as of the date of the financial statements and reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates and assumptions by management affect the Company’s allowance for doubtful accounts, the net realizable value of inventory, fair value of warrant liability, valuation of market based awards, valuations and purchase price allocations related to investments and business combinations, expected future cash flows including growth rates, discount rates, terminal values and other assumptions and estimates used to evaluate the recoverability of long-lived assets, estimated fair values of intangible assets and goodwill, amortization methods and periods, certain accrued expenses, share-based compensation, contingent consideration from business combinations, tax reserves, and the recoverability of the Company’s net deferred tax assets and the related valuation allowance. The Company regularly assesses these estimates; however, actual results could differ materially from these estimates. Changes in estimates are recorded in the period in which they become known. The Company bases its estimates on historical experience and various other assumptions that it believes to be reasonable under the circumstances.
Basis of Accounting, Policy [Policy Text Block]	Basis of presentation The Unaudited Condensed Consolidated Financial Statements included herein have been prepared by BioLife in accordance with U.S. GAAP and pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”), for Quarterly Reports on Form 10 10 X not 10 December 31, 2020. The Unaudited Condensed Consolidated Financial Statements include the accounts of the Company and its wholly-owned subsidiaries, Astero Bio Corporation (“Astero,” and the Astero product line, “ThawStar” acquired on April 1, 2019), August 8, 2019), November 12, 2019), October 1, 2020), May 3, 2021), September 1, 2021). In the opinion of management, the accompanying Unaudited Condensed Consolidated Financial Statements include all adjustments, consisting of only normal, recurring adjustments necessary for a fair presentation of the financial position, results of operations, and cash flows. The results of operations for the interim periods presented are not Financial Statement Reclassification Certain classifications on the Unaudited Condensed Consolidated Balance Sheets related to accrued expenses and other current liabilities, debt, current portion, and debt, long-term as of December 31, 2020 no
Segment Reporting, Policy [Policy Text Block]	Segment reporting The Company operates and manages its business as one
Liquidity and Capital Resources, Policy [Policy Text Block]	Liquidity and capital resources On September 30, 2021 December 31, 2020, may may not
Risk and Uncertainties, Policy [Policy Text Block]	Risks and uncertainties On March 10, 2020, 2, 2019 19” 19 19, 19. not 19, The Company may 19 third Any disruption and volatility in the global capital markets as a result of the pandemic may 19 not The ultimate extent to which the COVID- 19 19 On March 27, 2020, As of March 30, 2020, September 30, 2021, 2021 2022. On March 11, 2021, 2021” In the SciSafe acquisition, the Company assumed a $295,300 loan from the PPP. The loan incurs interest at 1% and is unsecured. Should any portion of the principal of the note not October 2022. no
Concentration Risk, Credit Risk, Policy [Policy Text Block]	Concentrations of credit risk and business risk We derived approximately 19% and 14% of revenue from one three nine September 30, 2021, one three nine September 30, 2020, No 10% three nine September 30, 2021 2020. The following table represents the Company’s total revenue by geographic area (based on the location of the customer): Three Months Ended Nine Months Ended September 30, September 30, Revenue by customers geographic locations 2021 2020 2021 2020 North America 88 % 84 % 87 % 86 % Europe, Middle East, Africa (EMEA) 9 % 13 % 10 % 12 % Other 3 % 3 % 3 % 2 % Total revenue 100 % 100 % 100 % 100 % We derived approximately 30% and 33% of our revenue from CryoStor products in the three nine September 30, 2021, three nine September 30, 2020. 780XLE three nine September 30, 2021, 780XLE not 10% three nine September 30, 2020. As of September 30, 2021 December 31, 2020, two one No 10% September 30, 2021 December 31, 2020. As of September 30, 2021 December 31, 2020, one No 10% September 30, 2021 December 31, 2020.
New Accounting Pronouncements, Policy [Policy Text Block]	Recent accounting pronouncements In October 2021, 2021 08, 805 Accounting for Contract Assets and Contract Liabilities from Contracts with Customers 606 606 2021 08 December 15, 2022, In July 2021, 2021 05, 842 Lessors - Certain Leases with Variable Lease Payments 2021 05" 2021 05 840. not 1 842 10 25 2 25 3; 2 one 2021 05 December 15, 2021, 2021 05 In May 2021, No. 2021 04, Issuer s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options 2021 04 2021 04 December 15, 2021, 2021 04 not not In August 2020, No. 2020 06, Debt - Debt with Conversion and Other Options (Subtopic 470 20 s Own Equity (Subtopic 815 40 2020 06 2020 06 2020 06 December 15, 2021, no December 15, 2020. not In March 2020, No. 2020 04, Reference Rate Reform (Topic 848 January 2021, 2021 01, no December 1, 2022, not In June 2016, No. 2016 13, Financial Instruments Credit Losses (Topic 326 2016 13 2016 13 December 15, 2023,

Note 1 - Organization and Sig_2

Note 1 - Organization and Significant Accounting Policies (Tables)	9 Months Ended
	Sep. 30, 2021
Notes Tables
Revenue from External Customers by Products and Services [Table Text Block]	Three Months Ended Nine Months Ended September 30, September 30, Revenue by customers geographic locations 2021 2020 2021 2020 North America 88 % 84 % 87 % 86 % Europe, Middle East, Africa (EMEA) 9 % 13 % 10 % 12 % Other 3 % 3 % 3 % 2 % Total revenue 100 % 100 % 100 % 100 %

Note 2 - Fair Value Measureme_2

Note 2 - Fair Value Measurement (Tables)	9 Months Ended
	Sep. 30, 2021
Notes Tables
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]	As of September 30, 2021 Level 1 Level 2 Level 3 Total Assets: Money market accounts $ 70,152 $ - $ - $ 70,152 Total 70,152 - - 70,152 Liabilities: Contingent consideration - business combinations - - 8,238 8,238 Total $ - $ - $ 8,238 $ 8,238 As of December 31, 2020 Level 1 Level 2 Level 3 Total Assets: Money market accounts $ 90,403 $ - $ - $ 90,403 Total 90,403 - - 90,403 Liabilities: Contingent consideration - business combinations - - 7,152 7,152 Warrant liability - - 2,780 2,780 Total $ - $ - $ 9,932 $ 9,932
Warrant Liabilities [Member]
Notes Tables
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	Nine Months Ended September 30, (In thousands) 2021 2020 Beginning balance $ 2,780 $ 39,602 Exercised warrants (2,901 ) (33,221 ) Change in fair value recognized in net income (loss) 121 (4,467 ) Ending balance $ - $ 1,914
Contingent Consideration Liabilities [Member]
Notes Tables
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	Nine Months Ended September 30, (In thousands) 2021 2020 Beginning balance $ 7,152 $ 1,914 Change in fair value recognized in net income (loss) 1,086 (1,528 ) Ending balance $ 8,238 $ 386

Note 3 - Acquisitions (Tables)

Note 3 - Acquisitions (Tables)	9 Months Ended
	Sep. 30, 2021
Notes Tables
Schedule of Business Acquisitions, by Acquisition [Table Text Block]	Merger consideration shares 530,502 BioLife stock price (as of September 1, 2021) $ 60.50 Value of issued shares $ 32,095 plus: Fair value of BioLife’s existing investment in Sexton $ 7,951 less: Net working capital adjustment $ (118 ) Merger Consideration $ 39,928 BioLife shares outstanding (as of March 19, 2021) 33,401,359 Merger consideration percentage 19.9 % Merger consideration shares 6,646,870 less: Merger consideration shares withheld to satisfy outstanding GCI stockholder obligations to GCI 10,400 Subtotal 6,636,470 BioLife stock price (as of May 3, 2021) $ 35.07 Value of issued shares $ 232,741 plus: Settlement of BioLife prepaid deposits $ 2,152 plus: Net settlement of BioLife accounts receivable $ 16 Merger Consideration $ 234,909
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]	Cash $ 1,516 Accounts receivable, net 492 Inventory 1,310 Prepaid expenses and other current assets 670 Property, plant and equipment, net 737 Operating lease right-of-use assets, net 470 Developed technology 4,132 Customer relationships 2,276 Tradenames 2,324 Non-compete agreements 90 Goodwill 28,273 Accounts payable (291 ) Lease liabilities, operating (470 ) Deferred tax liability (1,284 ) Other liabilities (317 ) Fair value of net assets acquired $ 39,928 Cash $ 43 Accounts receivable, net 7,076 Inventory 15,547 Prepaid expenses and other current assets 639 Property, plant and equipment, net 3,512 Operating lease right-of-use assets, net 1,741 Financing lease right-of-use assets, net 114 Long-term deposits and other assets 4 Developed technology 18,140 Customer relationships 7,020 Tradenames 26,640 Non-compete agreements 1,240 In-process research and development 67,440 Goodwill 137,215 Accounts payable (9,837 ) Line of credit (4,231 ) Lease liabilities, operating (1,880 ) Lease liabilities, financing (114 ) Long-term debt (4,410 ) Deferred tax liability (23,526 ) Other liabilities (7,464 ) Fair value of net assets acquired $ 234,909
Schedule of Acquired Finite-Lived Intangible Assets by Major Class [Table Text Block]	Fair Value Useful Life (Years) Developed technology $ 4,132 5 - 9 Customer relationships 2,276 2 Tradenames 2,324 11 Non-compete agreements 90 1 Total identifiable intangible assets $ 8,822 Fair Value Useful Life (Years) Developed technology $ 18,140 6 Customer relationships 7,020 12 Tradenames 26,640 15 Non-compete agreements 1,240 4 In-process research and development 67,440 N/A Total identifiable intangible assets $ 120,480
Business Acquisition, Pro Forma Information [Table Text Block]	Three Months Ended Nine Months Ended September 30, September 30, (In thousands) 2021 (unaudited) 2020 (unaudited) 2021 (unaudited) 2020 (unaudited) Total revenue $ 34,524 $ 11,697 $ 85,189 $ 34,707 Net (loss) income $ (685 ) $ (1,850 ) $ 4,612 $ 2,056 Three Months Ended Nine Months Ended September 30, September 30, (In thousands) 2021 (unaudited) 2020 (unaudited) 2021 (unaudited) 2020 (unaudited) Total revenue $ 33,800 $ 21,204 $ 106,427 $ 58,056 Net income (loss) $ 79 $ (3,393 ) $ (1,939 ) $ 4,912

Note 4 - Inventory (Tables)

Note 4 - Inventory (Tables)	9 Months Ended
	Sep. 30, 2021
Notes Tables
Schedule of Inventory, Current [Table Text Block]	(In thousands) 2021 2020 Raw materials $ 16,445 $ 2,855 Work in progress 4,597 2,006 Finished goods 8,654 6,741 Total $ 29,696 $ 11,602

Note 5 - Assets Held for Rent (

Note 5 - Assets Held for Rent (Tables)	9 Months Ended
	Sep. 30, 2021
Notes Tables
Scheduleof Assets Held for Rent [Table Text Block]	(In thousands) 2021 2020 Shippers placed in service $ 5,433 $ 3,171 Fixed assets held for rent 3,603 - Accumulated depreciation (1,284 ) (411 ) Net 7,752 2,760 Shippers and related components in production 2,334 1,945 Total $ 10,086 $ 4,705

Note 6 - Goodwill and Intangi_2

Note 6 - Goodwill and Intangible Assets (Tables)	9 Months Ended
	Sep. 30, 2021
Notes Tables
Schedule of Finite-Lived Intangible Assets [Table Text Block]	(In thousands, except weighted average useful life) September 30, 2021 Finite-lived intangible assets: Gross Carrying Value Accumulated Amortization Net Carrying Value Weighted Average Usefu l Life (in years) Customer Relationships $ 17,516 $ (1,177 ) $ 16,339 10.8 Tradenames 35,574 (1,672 ) 33,902 14.4 Technology - acquired 41,942 (6,300 ) 35,642 6.1 Non-compete agreements 1,990 (302 ) 1,688 3.3 In-process research and development⁽¹⁾ 67,440 - 67,440 N/A Total intangible assets $ 164,462 $ (9,451 ) $ 155,011 10.1 December 31, 2020 Finite-lived intangible assets: Gross Carrying Value Accumulated Amortization Net Carrying Value Weighted Average Useful Life (in years) Customer Relationships $ 8,220 $ (330 ) $ 7,890 12.8 Tradenames 6,610 (508 ) 6,102 14.0 Technology - acquired 19,670 (3,232 ) 16,438 7.1 Non-compete agreements 660 (41 ) 619 3.8 Total intangible assets $ 35,160 $ (4,111 ) $ 31,049 9.7
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]	(In thousands) For the Years Ending December 31, Estimated Amortization Expense 2021 (3 months remaining) $ 2,858 2022 11,403 2023 10,934 2024 10,109 2025 9,730 Thereafter 42,537 Total $ 87,571

Note 7 - Line of Credit and L_2

Note 7 - Line of Credit and Long-term Debt (Tables)	9 Months Ended
	Sep. 30, 2021
Notes Tables
Schedule of Debt [Table Text Block]	September 30, December 31, (In thousands) Maturity Date Interest Rate 2021 2020 2019 term loan Sep-23 10.5 % $ 1,750 $ - 2018 term loan Sep-23 10.5 % 2,813 - Insurance premium financing Apr-22 4.0 % 726 - Paycheck Protection Program loan May-22 1.0 % 295 295 Freezer equipment loan Dec-25 5.7 % 652 365 Manufacturing equipment loans Oct-25 5.7 % 376 439 Freezer installation loan Various 6.3 % 1,395 156 Other loans Various Various 10 14 Total debt 8,017 1,269 Less: Unamortized debt issuance costs (124 ) - Total debt, net of unamortized debt issuance costs $ 7,893 $ 1,269
Schedule of Maturities of Long-term Debt [Table Text Block]	(In thousands) Amount 2021 (3 months remaining) $ 950 2022 1,208 2023 2,038 2024 1,944 2025 543 Thereafter 1,334 Total $ 8,017

Note 8 - Share-based Compensa_2

Note 8 - Share-based Compensation (Tables)	9 Months Ended
	Sep. 30, 2021
Notes Tables
Share-based Payment Arrangement, Option, Activity [Table Text Block]	Nine Months Ended September 30, 2021 Shares Wtd. Avg. Exercise Price Outstanding as of beginning of year 844,455 $ 2.00 Exercised (131,590 ) 1.48 Forfeited (1,146 ) 5.69 Expired (35,714 ) 1.73 Outstanding as of September 30, 2021 676,005 $ 2.12 Stock options exercisable as of September 30, 2021 671,964 $ 2.11 Nine Months Ended September 30, 2021 Shares Wtd. Avg. Exercise Price Outstanding as of beginning of year 686,001 $ 1.64 Exercised (501,075 ) 1.64 Outstanding as of September 30, 2021 184,926 $ 1.64 Stock options exercisable as of September 30, 2021 184,926 $ 1.64
Share-based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]	Nine Months Ended September 30, 2021 Shares Wtd. Avg. Grant Date Fair Value Outstanding as of beginning of year 930,854 $ 19.31 Granted 751,363 47.50 Vested (241,590 ) 15.97 Forfeited (79,079 ) 34.86 Non-vested as of September 30, 2021 1,361,548 $ 34.56 Nine Months Ended September 30, 2021 Shares Wtd. Avg. Grant Date Fair Value Outstanding as of beginning of year 224,774 $ 19.20 Granted 152,665 30.85 Vested (231,268 ) 26.98 Non-vested as of September 30, 2021 146,171 $ 20.78
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]	Three Months Ended Nine Months Ended September 30, September 30, 2021 2020 2021 2020 Research and development costs $ 551 $ 291 $ 1,171 $ 687 Sales and marketing costs 560 256 1,012 581 General and administrative costs 3,015 868 5,662 2,144 Cost of revenue 742 145 1,047 406 Total $ 4,868 $ 1,560 $ 8,892 $ 3,818

Note 9 - Warrants (Tables)

Note 9 - Warrants (Tables)	9 Months Ended
	Sep. 30, 2021
Notes Tables
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	Shares Wtd. Avg. Exercise Price Outstanding as of December 31, 2020 79,100 $ 4.75 Exercised (79,100 ) 4.75 Outstanding and exercisable as of September 30, 2021 - $ -

Note 11 - Net (Loss) Income P_2

Note 11 - Net (Loss) Income Per Common Share (Tables)	9 Months Ended
	Sep. 30, 2021
Notes Tables
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	Three Months Ended Nine Months Ended September 30, September 30, (In thousands, except share and earnings per share data) 2021 2020 2021 2020 Basic earnings (loss) per common share Numerator: Net income (loss) $ 79 $ (1,133 ) $ 6,837 $ 4,795 Amount attributable to unvested restricted shares (2 ) - (212 ) (138 ) Amount attributable to warrants outstanding - - (4 ) (335 ) Net income (loss) allocated to common shareholders 77 (1,133 ) 6,621 4,322 Denominator: Weighted-average common shares issued and outstanding 40,911,801 31,639,420 37,435,224 25,418,375 Basic earnings (loss) per common share $ 0.00 $ (0.04 ) $ 0.18 $ 0.17 Diluted earnings (loss) per common share Numerator: Net income (loss) $ 79 $ (1,133 ) $ 6,837 $ 4,795 Amount attributable to unvested restricted shares (2 ) - (205 ) - Amount attributable to warrants - - (4 ) (49 ) Less: gain related to change in fair value of warrants - - - (4,467 ) Diluted earnings (loss) per common share 77 (1,133 ) 6,628 279 Denominator: Weighted-average common shares issued and outstanding 40,911,801 31,639,420 37,435,224 25,418,375 Dilutive potential common shares from: Stock options 1,069,207 - 1,330,207 1,754,051 Restricted shares 1,315,462 - 1,195,154 285,975 Warrants - - 24,338 1,954,137 Diluted weighted average shares issued and outstanding 43,296,470 31,639,420 39,984,923 29,412,538 Diluted earnings (loss) per common share $ 0.00 $ (0.04 ) $ 0.17 $ 0.01
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	Three Months Ended Nine Months Ended September 30, September 30, 2021 2020 2021 2020 Stock options and restricted stock awards - 2,183,537 - - Warrants - 62,769 - - Total - 2,246,306 - -

Note 13 - Revenue (Tables)

Note 13 - Revenue (Tables)	9 Months Ended
	Sep. 30, 2021
Notes Tables
Revenues By Product Line [Table Text Block]	Three Months Ended Nine Months Ended September 30, September 30, (In thousands, except percentages) 2021 2020 2021 2020 Product revenue Freezer and thaw $ 17,610 $ 3,371 $ 40,021 $ 9,237 Cell processing 11,505 7,414 30,131 22,753 Storage and cold chain services 86 19 293 30 Service revenue Storage and cold chain services 2,250 - 6,417 - Rental revenue Storage and cold chain services 2,349 475 4,989 1,341 Total revenue $ 33,800 $ 11,279 $ 81,851 $ 33,361
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table Text Block]	Year Ending December 31, (In thousands) 2021 2022 2023 2024 Total Rental revenue $ 2,983 $ 7,733 $ 422 $ - $ 11,138 Service revenue $ 40 $ 31 $ 31 $ 10 $ 112

Note 14 - Leases (Tables)

Note 14 - Leases (Tables)	9 Months Ended
	Sep. 30, 2021
Notes Tables
Lessee, Operating and Finance Lease Term And Discount Rate [Table Text Block]	September 30, December 31, (In thousands) 2021 2020 Weighted average discount rate - operating leases 3.6 % 3.3 % Weighted average discount rate - finance leases 6.1 % 5.7 % Weighted average remaining lease term in years - operating leases 7.9 1.5 Weighted average remaining lease term in years - finance leases 3.2 0.9
Lease, Cost [Table Text Block]	Three Months Ended Nine Months Ended September 30, September 30, (In thousands) 2021 2020 2021 2020 Operating lease costs $ 805 $ 170 $ 1,998 $ 509 Short-term lease costs 498 59 1,158 176 Total operating lease costs 1,303 229 3,156 685 Variable lease costs 193 - 477 - Total lease expense $ 1,496 $ 229 $ 3,633 $ 685
Lessee, Operating Lease, Liability, Maturity [Table Text Block]	(In thousands) Operating Leases Financing Leases 2021 (3 months remaining) $ 890 $ 43 2022 3,108 171 2023 2,760 171 2024 2,523 101 2025 2,245 37 Thereafter 8,780 1 Total lease payments 20,306 524 Less: interest (2,611 ) (49 ) Total present value of lease liabilities $ 17,695 $ 475

Note 15 - Unaudited Condensed_2

Note 15 - Unaudited Condensed Consolidated Balance Sheet Detail (Tables)	9 Months Ended
	Sep. 30, 2021
Notes Tables
Property, Plant and Equipment [Table Text Block]	September 30, December 31, (In thousands) 2021 2020 Property and equipment Leasehold improvements $ 3,301 $ 2,393 Furniture and computer equipment 1,793 902 Manufacturing and other equipment 13,798 10,076 Construction in-progress 4,747 591 Subtotal 23,639 13,962 Less: Accumulated depreciation (6,177 ) (3,842 ) Net property and equipment $ 17,462 $ 10,120
Schedule of Accrued Liabilities [Table Text Block]	September 30, December 31, (In thousands) 2021 2020 Accrued expenses $ 1,435 $ 472 Accrued taxes 62 112 Accrued compensation 4,167 2,898 Warranty reserve liability 5,552 212 Deferred revenue, current 710 931 Other 131 130 Total accrued expenses and other current liabilities $ 12,057 $ 4,755
Schedule of Product Warranty Liability [Table Text Block]	Nine Months Ended September 30, (In thousands) 2021 2020 Beginning balance $ 212 $ 191 Warranty reserve acquired in the acquisition of Global Cooling 3,353 - Provision for warranties 4,446 109 Settlements of warranty claims (2,459 ) (92 ) Ending Balance $ 5,552 $ 208

Note 1 - Organization and Sig_3

Note 1 - Organization and Significant Accounting Policies (Details Textual)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2021USD ($)	Sep. 30, 2020	Sep. 30, 2021USD ($)	Sep. 30, 2020	Dec. 31, 2020USD ($)	Oct. 01, 2020USD ($)
Number of Reportable Segments			1
Number of Operating Segments			1
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Ending Balance	$ 75,100,000		$ 75,100,000		$ 90,400,000
Deferred Tax Payments, Social Security	$ 432,000		$ 432,000
Deferred Social Security Tax Payments Payback, Percentage Tranche One	50.00%		50.00%
Deferred Social Security Tax Payments Payback, Percentage Tranche Two	50.00%		50.00%
Customer Concentration Risk [Member] | Revenue Benchmark [Member]
Number of Major Customers	1	1	1	1
Customer Concentration Risk [Member] | Revenue Benchmark [Member] | CryoStor Products [Member]
Concentration Risk, Percentage	30.00%	62.00%	33.00%	64.00%
Customer Concentration Risk [Member] | Revenue Benchmark [Member] | 780XLE Freezer Line [Member]
Concentration Risk, Percentage	29.00%		21.00%
Customer Concentration Risk [Member] | Revenue Benchmark [Member] | One Customer [Member]
Concentration Risk, Percentage	19.00%	11.00%	14.00%	12.00%
Customer Concentration Risk [Member] | Accounts Receivable [Member]
Number of Major Customers			2		1
Customer Concentration Risk [Member] | Accounts Receivable [Member] | One Customer [Member]
Concentration Risk, Percentage					17.00%
Customer Concentration Risk [Member] | Accounts Receivable [Member] | Two Customers [Member]
Concentration Risk, Percentage			29.00%
Supplier Concentration Risk [Member] | Accounts Payable [Member]
Number of Suppliers			1		1
Supplier Concentration Risk [Member] | Accounts Payable [Member] | One Supplier [Member]
Concentration Risk, Percentage			11.00%		21.00%
Paycheck Protection Program CARES Act [Member]
Debt Instrument, Interest Rate, Stated Percentage	1.00%		1.00%
Paycheck Protection Program CARES Act [Member] | SciSafe Holdings, Inc [Member]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-term Debt						$ 295,300
Debt Instrument, Interest Rate, Stated Percentage						1.00%

Note 1 - Organization and Sig_4

Note 1 - Organization and Significant Accounting Policies - Concentrations Risk by Geographic Locations (Details) - Revenue Benchmark [Member] - Geographic Concentration Risk [Member]	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Revenue by customers’ geographic locations, percentage	100.00%	100.00%	100.00%	100.00%
North America [Member]
Revenue by customers’ geographic locations, percentage	88.00%	84.00%	87.00%	86.00%
EMEA [Member]
Revenue by customers’ geographic locations, percentage	9.00%	13.00%	10.00%	12.00%
Geographic, Other [Member]
Revenue by customers’ geographic locations, percentage	3.00%	3.00%	3.00%	2.00%

Note 2 - Fair Value Measureme_3

Note 2 - Fair Value Measurement (Details Textual)	3 Months Ended		9 Months Ended
	Sep. 30, 2021USD ($)	Sep. 30, 2020USD ($)	Sep. 30, 2021USD ($)	Sep. 30, 2020USD ($)	Dec. 31, 2020USD ($)	Oct. 01, 2020USD ($)	Nov. 10, 2019	Apr. 01, 2019
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability	$ (140,000)	$ (2,000)	$ 1,086,000	$ (1,528,000)
Measurement Input, Price Volatility [Member] | Minimum [Member]
Warrants and Rights Outstanding, Measurement Input					0.568
Measurement Input, Price Volatility [Member] | Maximum [Member]
Warrants and Rights Outstanding, Measurement Input					0.846
Astero [Member]
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability	0		(81,000)
Business Combination, Contingent Consideration, Liability, Total					$ 81,000
Astero [Member] | Measurement Input, Discount Rate [Member]
Business Combination, Contingent Consideration, Liability, Measurement Input								0.175
Astero [Member] | Measurement Input, Risk Free Interest Rate [Member] | Minimum [Member]
Business Combination, Contingent Consideration, Liability, Measurement Input								0.0229
Astero [Member] | Measurement Input, Risk Free Interest Rate [Member] | Maximum [Member]
Business Combination, Contingent Consideration, Liability, Measurement Input								0.0241
Astero [Member] | Measurement Input, Price Volatility [Member]
Business Combination, Contingent Consideration, Liability, Measurement Input								0.56
CBS Acquisition [Member]
Business Combination, Contingent Consideration, Liability, Total	$ 140,000		$ 140,000		140,000
CBS Acquisition [Member] | Measurement Input, Discount Rate [Member]
Business Combination, Contingent Consideration, Liability, Measurement Input	0.210		0.210				0.260
CBS Acquisition [Member] | Measurement Input, Risk Free Interest Rate [Member]
Business Combination, Contingent Consideration, Liability, Measurement Input	0.0023		0.0023				0.0174
CBS Acquisition [Member] | Measurement Input, Price Volatility [Member]
Business Combination, Contingent Consideration, Liability, Measurement Input	0.63		0.63				0.70
SciSafe Holdings, Inc [Member]
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability	$ (141,000)		$ 1,200,000
Business Combination, Contingent Consideration, Liability, Total	$ 8,100,000		$ 8,100,000		$ 6,900,000	$ 3,700,000
SciSafe Holdings, Inc [Member] | Measurement Input, Discount Rate [Member]
Business Combination, Contingent Consideration, Liability, Measurement Input	0.068		0.068			0.045
SciSafe Holdings, Inc [Member] | Measurement Input, Risk Free Interest Rate [Member]
Business Combination, Contingent Consideration, Liability, Measurement Input	0.0047		0.0047			0.0020
SciSafe Holdings, Inc [Member] | Measurement Input, Asset Price Volatility [Member]
Business Combination, Contingent Consideration, Liability, Measurement Input	0.61		0.61			0.60
SciSafe Holdings, Inc [Member] | Measurement Input, Revenue Volatility [Member]
Business Combination, Contingent Consideration, Liability, Measurement Input	0.22		0.22			0.15

Note 2 - Fair Value Measureme_4

Note 2 - Fair Value Measurement - Financial Assets and Liabilities on Recurring Basis (Details) - Fair Value, Recurring [Member] - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Assets	$ 70,152	$ 90,403
Liabilities	8,238	9,932
Contingent Consideration Liabilities [Member]
Liabilities	8,238
Warrant Liabilities [Member]
Liabilities		2,780
Money Market Funds [Member]
Assets	70,152	90,403
Contingent Consideration Liabilities [Member]
Liabilities		7,152
Fair Value, Inputs, Level 1 [Member]
Assets	70,152	90,403
Liabilities	0	0
Fair Value, Inputs, Level 1 [Member] | Contingent Consideration Liabilities [Member]
Liabilities	0
Fair Value, Inputs, Level 1 [Member] | Warrant Liabilities [Member]
Liabilities		0
Fair Value, Inputs, Level 1 [Member] | Money Market Funds [Member]
Assets	70,152	90,403
Fair Value, Inputs, Level 1 [Member] | Contingent Consideration Liabilities [Member]
Liabilities		0
Fair Value, Inputs, Level 2 [Member]
Assets	0	0
Liabilities	0	0
Fair Value, Inputs, Level 2 [Member] | Contingent Consideration Liabilities [Member]
Liabilities	0
Fair Value, Inputs, Level 2 [Member] | Warrant Liabilities [Member]
Liabilities		0
Fair Value, Inputs, Level 2 [Member] | Money Market Funds [Member]
Assets	0	0
Fair Value, Inputs, Level 2 [Member] | Contingent Consideration Liabilities [Member]
Liabilities		0
Fair Value, Inputs, Level 3 [Member]
Assets	0	0
Liabilities	8,238	9,932
Fair Value, Inputs, Level 3 [Member] | Contingent Consideration Liabilities [Member]
Liabilities	8,238
Fair Value, Inputs, Level 3 [Member] | Warrant Liabilities [Member]
Liabilities		2,780
Fair Value, Inputs, Level 3 [Member] | Money Market Funds [Member]
Assets	$ 0	0
Fair Value, Inputs, Level 3 [Member] | Contingent Consideration Liabilities [Member]
Liabilities		$ 7,152

Note 2 - Fair Value Measureme_5

Note 2 - Fair Value Measurement - Fair Value of Contingent Consideration Using Level 3 Inputs (Details) - Contingent Consideration Liabilities [Member] - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Beginning balance	$ 7,152	$ 1,914
Change in fair value recognized in net income (loss)	(1,086)	1,528
Ending balance	$ 8,238	$ 386

Note 2 - Fair Value Measureme_6

Note 2 - Fair Value Measurement - Fair Value of Warrant Liabilities Using Level 3 Inputs (Details) - Warrant Liabilities [Member] - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Beginning balance	$ 2,780	$ 39,602
Exercised warrants	(2,901)	(33,221)
Change in fair value recognized in net income (loss)	(121)	4,467
Ending balance	$ 0	$ 1,914

Note 3 - Acquisitions (Details

Note 3 - Acquisitions (Details Textual) - USD ($)	Sep. 01, 2021	May 03, 2021	Sep. 30, 2021	Sep. 30, 2021	Aug. 09, 2021	Dec. 31, 2020
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill, Total			$ 8,822,000	$ 8,822,000
Goodwill, Ending Balance			223,936,000	223,936,000		$ 58,449,000
Sexton Acquisition [Member]
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares (in shares)	530,502
Business Acquisition, Percentage of Equity Issuable Shares Held in Escrow Accounts for Post Closing Claims	10.00%
Business Combination, Step Acquisition, Equity Interest in Acquiree, Remeasurement Gain (Loss), Net, Total	$ 6,500,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Tangible Assets	4,100,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities	1,284,000				$ 1,300,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill, Total	8,800,000
Goodwill, Ending Balance	28,273,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Gross Receivables	509,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Uncollectable Receivables	$ 17,000
Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual			425,000
Business Combination, Pro Forma Information, Earnings or Loss of Acquiree since Acquisition Date, Actual			$ 227,000
Sexton Acquisition [Member] | Common Stock Issued to Acquire Participating Holders [Member]
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares (in shares)	477,452
Sexton Acquisition [Member] | Common Stock Deposited Into Escrow [Member]
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares (in shares)	53,050
GCI Acquisition [Member]
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares (in shares)		6,636,470
Business Acquisition, Percentage of Equity Issuable Shares Held in Escrow Accounts for Post Closing Claims		9.00%
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Tangible Assets		$ 740,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities		23,526,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill, Total		120,480,000
Goodwill, Ending Balance		137,215,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Gross Receivables		7,100,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Uncollectable Receivables		$ 53,000
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares, Before Adjustments (in shares)		6,646,870
Business Combination, Stock Reduced During Period, Satisfy Note Receivable (in shares)		10,400
Business Combination, Escrow Shares, Period (Month)		24 months
Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual				28,500,000
Business Combination, Pro Forma Information, Earnings or Loss of Acquiree since Acquisition Date, Actual				$ 7,600,000
GCI Acquisition [Member] | One GCI Stockholder [Member]
Business Combination, Stock Reduced During Period, Satisfy Note Receivable (in shares)		10,400
Financing Receivable, after Allowance for Credit Loss, Total		$ 374,000

Note 3 - Acquisitions - Conside

Note 3 - Acquisitions - Consideration (Details) - USD ($) $ / shares in Units, $ in Thousands	Sep. 01, 2021	May 03, 2021	Sep. 30, 2021	Sep. 30, 2020
BioLife stock price (in dollars per share)	$ 60.50	$ 35.07
Value of issued shares			$ 264,718	$ 0
BioLife shares outstanding (as of March 19, 2021) (in shares)		33,401,359
Value of issued shares			$ 264,718	$ 0
Sexton Acquisition [Member]
Merger consideration shares (in shares)	530,502
Value of issued shares	$ 32,095
plus: Fair value of BioLife’s existing investment in Sexton	7,951
less: Net working capital adjustment	(118)
Merger Consideration	$ 39,928
Stock consideration (in shares)	530,502
Value of issued shares	$ 32,095
GCI Acquisition [Member]
Merger consideration shares (in shares)		6,636,470
Value of issued shares		$ 232,741
Merger Consideration		$ 234,909
Merger consideration percentage		19.90%
Merger consideration shares (in shares)		6,646,870
less: Merger consideration shares withheld to satisfy outstanding GCI stockholder obligations to GCI (in shares)		10,400
Stock consideration (in shares)		6,636,470
Value of issued shares		$ 232,741
plus: Settlement of BioLife prepaid deposits		2,152
plus: Net settlement of BioLife accounts receivable		$ 16

Note 3 - Acquisitions - Fair Va

Note 3 - Acquisitions - Fair Value of Net Assets Acquired (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Sep. 01, 2021	Aug. 09, 2021	May 03, 2021	Dec. 31, 2020
Goodwill	$ 223,936				$ 58,449
Goodwill	223,936				$ 58,449
Sexton Acquisition [Member]
Cash		$ 1,516
Accounts receivable, net		492
Inventory		1,310
Prepaid expenses and other current assets		670
Property, plant and equipment, net		737
Operating lease right-of-use assets, net		470
Goodwill		28,273
Accounts payable		(291)
Lease liabilities, operating		(470)
Deferred tax liability		(1,284)	$ (1,300)
Other liabilities		(317)
Fair value of net assets acquired		39,928
Goodwill		28,273
Accounts payable		(291)
Lease liabilities, operating		(470)
Deferred tax liability		(1,284)	$ (1,300)
Other liabilities		(317)
Sexton Acquisition [Member] | Developed Technology Rights [Member]
Developed technology	4,132	4,132
Sexton Acquisition [Member] | Customer Relationships [Member]
Developed technology	2,276	2,276
Sexton Acquisition [Member] | Trade Names [Member]
Developed technology	2,324	2,324
Sexton Acquisition [Member] | Noncompete Agreements [Member]
Developed technology	$ 90	$ 90
GCI Acquisition [Member]
Cash				$ 43
Accounts receivable, net				7,076
Inventory				15,547
Prepaid expenses and other current assets				639
Property, plant and equipment, net				3,512
Operating lease right-of-use assets, net				1,741
Goodwill				137,215
Accounts payable				(9,837)
Lease liabilities, operating				(1,880)
Deferred tax liability				(23,526)
Other liabilities				(7,464)
Fair value of net assets acquired				234,909
Financing lease right-of-use assets, net				114
Long-term deposits and other assets				4
Goodwill				137,215
Accounts payable				(9,837)
Line of credit				(4,231)
Lease liabilities, operating				(1,880)
Lease liabilities, financing				(114)
Long-term debt				(4,410)
Deferred tax liability				(23,526)
Other liabilities				(7,464)
GCI Acquisition [Member] | In Process Research and Development [Member]
In-process research and development				67,440
GCI Acquisition [Member] | Developed Technology Rights [Member]
Developed technology				18,140
GCI Acquisition [Member] | Customer Relationships [Member]
Developed technology				7,020
GCI Acquisition [Member] | Trade Names [Member]
Developed technology				26,640
GCI Acquisition [Member] | Noncompete Agreements [Member]
Developed technology				$ 1,240

Note 3 - Acquisitions - Acquire

Note 3 - Acquisitions - Acquired Intangible Assets (Details) - USD ($) $ in Thousands	May 03, 2021	Sep. 30, 2021	Sep. 01, 2021
Total identifiable intangible assets		$ 8,822
Sexton Acquisition [Member]
Total identifiable intangible assets			$ 8,800
Sexton Acquisition [Member] | Developed Technology Rights [Member]
Developed technology		$ 4,132	4,132
Sexton Acquisition [Member] | Developed Technology Rights [Member] | Minimum [Member]
Intangible assets, estimated useful life (Year)		5 years
Sexton Acquisition [Member] | Developed Technology Rights [Member] | Maximum [Member]
Intangible assets, estimated useful life (Year)		9 years
Sexton Acquisition [Member] | Customer Relationships [Member]
Developed technology		$ 2,276	2,276
Intangible assets, estimated useful life (Year)		2 years
Sexton Acquisition [Member] | Trade Names [Member]
Developed technology		$ 2,324	2,324
Intangible assets, estimated useful life (Year)		11 years
Sexton Acquisition [Member] | Noncompete Agreements [Member]
Developed technology		$ 90	$ 90
Intangible assets, estimated useful life (Year)		1 year
GCI Acquisition [Member]
Total identifiable intangible assets	$ 120,480
GCI Acquisition [Member] | Developed Technology Rights [Member]
Developed technology	$ 18,140
Intangible assets, estimated useful life (Year)	6 years
GCI Acquisition [Member] | Customer Relationships [Member]
Developed technology	$ 7,020
Intangible assets, estimated useful life (Year)	12 years
GCI Acquisition [Member] | Trade Names [Member]
Developed technology	$ 26,640
Intangible assets, estimated useful life (Year)	15 years
GCI Acquisition [Member] | Noncompete Agreements [Member]
Developed technology	$ 1,240
Intangible assets, estimated useful life (Year)	4 years
GCI Acquisition [Member] | In Process Research and Development [Member]
In-process research and development	$ 67,440

Note 3 - Acquisitions - Pro For

Note 3 - Acquisitions - Pro Forma Information (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Sexton Acquisition [Member]
Total revenue	$ 34,524	$ 11,697	$ 85,189	$ 34,707
Net income (loss)	(685)	(1,850)	4,612	2,056
GCI Acquisition [Member]
Total revenue	33,800	21,204	106,427	58,056
Net income (loss)	$ 79	$ (3,393)	$ (1,939)	$ 4,912

Note 4 - Inventory - Summary of

Note 4 - Inventory - Summary of Inventories (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Raw materials	$ 16,445	$ 2,855
Work in progress	4,597	2,006
Finished goods	8,654	6,741
Total	$ 29,696	$ 11,602

Note 5 - Assets Held for Rent_2

Note 5 - Assets Held for Rent (Details Textual) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Assets Held for Rent, Depreciation	$ 410,000	$ 186,000	$ 873,000	$ 581,000

Note 5 - Assets Held for Rent -

Note 5 - Assets Held for Rent - Assets Held for Rent (Details) - USD ($) $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Shippers placed in service	$ 5,433	$ 3,171
Fixed assets held for rent	3,603	0
Accumulated depreciation	(1,284)	(411)
Net	7,752	2,760
Shippers and related components in production	2,334	1,945
Total	$ 10,086	$ 4,705

Note 6 - Goodwill and Intangi_3

Note 6 - Goodwill and Intangible Assets (Details Textual) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Amortization of Intangible Assets, Total	$ 2,525,000	$ 706,000	$ 5,340,000	$ 2,100,000

Note 6 - Goodwill and Intangi_4

Note 6 - Goodwill and Intangible Assets - Intangible Assets (Details) - USD ($) $ in Thousands		9 Months Ended	12 Months Ended
		Sep. 30, 2021	Dec. 31, 2020
Gross Carrying Value			$ 35,160
Accumulated Amortization		$ (9,451)	(4,111)
Net Carrying Value		87,571	31,049
Total intangible assets, gross		164,462
Total intangible assets, net		155,011	$ 31,049
In Process Research and Development [Member]
In-process research and development	[1]	$ 67,440
Weighted Average [Member]
Weighted Average Useful Life (Year)		10 years 1 month 6 days	9 years 8 months 12 days
Customer Relationships [Member]
Gross Carrying Value		$ 17,516	$ 8,220
Accumulated Amortization		(1,177)	(330)
Net Carrying Value		$ 16,339	$ 7,890
Customer Relationships [Member] | Weighted Average [Member]
Weighted Average Useful Life (Year)		10 years 9 months 18 days	12 years 9 months 18 days
Trade Names [Member]
Gross Carrying Value		$ 35,574	$ 6,610
Accumulated Amortization		(1,672)	(508)
Net Carrying Value		$ 33,902	$ 6,102
Trade Names [Member] | Weighted Average [Member]
Weighted Average Useful Life (Year)		14 years 4 months 24 days	14 years
Technology-Based Intangible Assets [Member]
Gross Carrying Value		$ 41,942	$ 19,670
Accumulated Amortization		(6,300)	(3,232)
Net Carrying Value		$ 35,642	$ 16,438
Technology-Based Intangible Assets [Member] | Weighted Average [Member]
Weighted Average Useful Life (Year)		6 years 1 month 6 days	7 years 1 month 6 days
Noncompete Agreements [Member]
Gross Carrying Value		$ 1,990	$ 660
Accumulated Amortization		(302)	(41)
Net Carrying Value		$ 1,688	$ 619
Noncompete Agreements [Member] | Weighted Average [Member]
Weighted Average Useful Life (Year)		3 years 3 months 18 days	3 years 9 months 18 days
[1]	In-process R&D represents the fair value of incomplete research and development that has not yet reached technological feasibility. We will amortize the asset upon technological feasibility.

Note 6 - Goodwill and Intangi_5

Note 6 - Goodwill and Intangible Assets - Future Amortization Expense (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
2021 (3 months remaining)	$ 2,858
2022	11,403
2023	10,934
2024	10,109
2025	9,730
Thereafter	42,537
Total	$ 87,571	$ 31,049

Note 7 - Line of Credit and L_3

Note 7 - Line of Credit and Long-term Debt (Details Textual) - USD ($)	9 Months Ended
	Sep. 30, 2021	Oct. 01, 2021
Line of Credit [Member]
Line of Credit Facility, Maximum Borrowing Capacity	$ 5,000,000
Line of Credit [Member] | London Interbank Offered Rate (LIBOR) [Member]
Debt Instrument, Basis Spread on Variable Rate	5.50%
Notes Payable [Member] | Advantage Term Note 1 [Member] | Subsequent Event [Member]
Debt Instrument, Face Amount		$ 1,400,000
Debt Instrument, Interest Rate, Stated Percentage		4.00%
Notes Payable [Member] | Advantage Term Note 2 [Member] | Subsequent Event [Member]
Debt Instrument, Face Amount		$ 1,400,000
Debt Instrument, Interest Rate, Stated Percentage		4.00%
Notes Payable [Member] | Enhanced Term Note [Member] | Subsequent Event [Member]
Debt Instrument, Face Amount		$ 1,800,000
Debt Instrument, Interest Rate, Stated Percentage		4.00%

Note 7 - Line of Credit and L_4

Note 7 - Line of Credit and Long-term Debt - Long-term Debt (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Total debt	$ 8,017	$ 1,269
Less: Unamortized debt issuance costs	(124)	0
Total debt, net of unamortized debt issuance costs	$ 7,893	1,269
The 2019 Term Loan [Member]
Interest rate	10.50%
Total debt	$ 1,750	0
The 2018 Term Loan [Member]
Interest rate	10.50%
Total debt	$ 2,813	0
Financed Insurance Premium [Member]
Interest rate	4.00%
Total debt	$ 726	0
Paycheck Protection Program CARES Act [Member]
Interest rate	1.00%
Total debt	$ 295	295
Freezer Equipment Loan [Member]
Interest rate	5.70%
Total debt	$ 652	365
Manufacturing Equipment Loans [Member]
Interest rate	5.70%
Total debt	$ 376	439
Freezer Installation Loan [Member]
Interest rate	6.30%
Total debt	$ 1,395	156
Other Loans [Member]
Total debt	$ 10	$ 14

Note 7 - Line of Credit and L_5

Note 7 - Line of Credit and Long-term Debt - Maturities of Loans Payable (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
2021 (3 months remaining)	$ 950
2022	1,208
2023	2,038
2024	1,944
2025	543
Thereafter	1,334
Total	$ 8,017	$ 1,269

Note 8 - Share-based Compensa_3

Note 8 - Share-based Compensation (Details Textual) - USD ($)	May 03, 2021	Feb. 08, 2021	Mar. 25, 2020	Apr. 01, 2019	Feb. 25, 2019	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020
Share-based Payment Arrangement, Expense						$ 4,868,000	$ 1,560,000	$ 8,892,000	$ 3,818,000
Share-based Payment Arrangement, Option [Member]
Share-based Payment Arrangement, Expense						6,000	15,000	21,000	104,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value						27,200,000		27,200,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value						27,000,000		27,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value						1,400,000	2,200,000	$ 5,200,000	6,800,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term (Year)								3 years 3 months 18 days
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total						4,000		$ 4,000
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)								2 months 12 days
Performance Shares [Member] | Management Performance Bonus Plan 2017 [Member]
Share-based Payment Arrangement, Expense						0	0	$ 0	0
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value						7,500,000		7,500,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value						7,500,000		7,500,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value						$ 9,700,000	$ 0	$ 19,500,000	$ 239,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term (Year)								2 months 12 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)						0	0	0	0
Restricted Stock [Member]
Share-based Payment Arrangement, Expense						$ 4,400,000	$ 754,000	$ 8,000,000	$ 1,600,000
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total						41,700,000		$ 41,700,000
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)								3 years 3 months 18 days
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Fair Value						31,100,000	4,200,000	$ 35,700,000	7,400,000
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value						5,100,000	1,600,000	$ 10,300,000	2,900,000
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)								751,363
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period (in shares)								241,590
Performance-based Restricted Stock [Member]
Share-based Payment Arrangement, Expense						0	191,000	$ 186,000	$ 569,000
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total						0		0
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)									20,285
Market-based Restricted Stock [Member]
Share-based Payment Arrangement, Expense						413,000	$ 600,000	1,100,000	$ 1,500,000
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total						$ 1,400,000		$ 1,400,000
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)								1 year 1 month 6 days
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)	6,415	30,616	109,140	29,604	94,247			152,665
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period (in shares)		231,268						231,268
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number, Ending Balance	68.00%	68.00%	78.00%	69.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate	0.00%	0.00%	0.00%	0.00%
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant	0.20%	0.10%	0.30%	2.50%
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)	2 years	2 years		2 years
Market-based Restricted Stock [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Awards	200.00%	200.00%	200.00%	200.00%
Market-based Restricted Stock [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Awards	0.00%	0.00%	0.00%
Market-based Restricted Stock First Issuance [Member]
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total										$ 3,100,000

Note 8 - Share-based Compensa_4

Note 8 - Share-based Compensation - Stock Option Activity (Details) - $ / shares	9 Months Ended
	Sep. 30, 2021
Share-based Payment Arrangement, Option [Member]
Outstanding (in shares)	844,455
Outstanding, weighted average exercise price (in dollars per share)	$ 2
Exercised (in shares)	(131,590)
Exercised, weighted average exercise price (in dollars per share)	$ 1.48
Forfeited (in shares)	(1,146)
Forfeited, weighted average exercise price (in dollars per share)	$ 5.69
Expired (in shares)	(35,714)
Expired, weighted average exercise price (in dollars per share)	$ 1.73
Outstanding (in shares)	676,005
Outstanding as of September 30, 2021 (in dollars per share)	$ 2.12
Options exercisable (in shares)	671,964
Options exercisable, weighted average exercise price (in dollars per share)	$ 2.11
Performance Shares [Member]
Outstanding (in shares)	686,001
Outstanding, weighted average exercise price (in dollars per share)	$ 1.64
Exercised (in shares)	(501,075)
Exercised, weighted average exercise price (in dollars per share)	$ 1.64
Outstanding (in shares)	184,926
Outstanding as of September 30, 2021 (in dollars per share)	$ 1.64
Options exercisable (in shares)	184,926
Options exercisable, weighted average exercise price (in dollars per share)	$ 1.64

Note 8 - Share-based Compensa_5

Note 8 - Share-based Compensation - Restricted Stock Activity (Details) - $ / shares	May 03, 2021	Feb. 08, 2021	Mar. 25, 2020	Apr. 01, 2019	Feb. 25, 2019	Sep. 30, 2021
Restricted Stock [Member]
Outstanding as of beginning of year (in shares)						930,854
Outstanding at beginning of year, grant date fair value (in dollars per share)						$ 19.31
Granted (in shares)						751,363
Granted, grant date fair value (in dollars per share)						$ 47.50
Vested (in shares)						(241,590)
Vested, grant date fair value (in dollars per share)						$ 15.97
Forfeited (in shares)						(79,079)
Forfeited, grant date fair value (in dollars per share)						$ 34.86
Outstanding at end of year (in shares)						1,361,548
Outstanding at end of year, grant date fair value (in dollars per share)						$ 34.56
Market-based Restricted Stock [Member]
Outstanding as of beginning of year (in shares)						224,774
Outstanding at beginning of year, grant date fair value (in dollars per share)						$ 19.20
Granted (in shares)	6,415	30,616	109,140	29,604	94,247	152,665
Granted, grant date fair value (in dollars per share)						$ 30.85
Vested (in shares)		(231,268)				(231,268)
Vested, grant date fair value (in dollars per share)						$ 26.98
Outstanding at end of year (in shares)						146,171
Outstanding at end of year, grant date fair value (in dollars per share)						$ 20.78

Note 8 - Share-based Compensa_6

Note 8 - Share-based Compensation - Stock Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Stock compensation expense	$ 4,868	$ 1,560	$ 8,892	$ 3,818
Research and Development Expense [Member]
Stock compensation expense	551	291	1,171	687
Selling and Marketing Expense [Member]
Stock compensation expense	560	256	1,012	581
General and Administrative Expense [Member]
Stock compensation expense	3,015	868	5,662	2,144
Cost of Sales [Member]
Stock compensation expense	$ 742	$ 145	$ 1,047	$ 406

Note 9 - Warrants (Details Text

Note 9 - Warrants (Details Textual) - $ / shares	Mar. 25, 2021	May 14, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020	May 31, 2016	Mar. 31, 2014
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)			$ 0		$ 4.75
Class of Warrant or Right, Exercised During Period (in shares)			79,100
Warrants to Purchase Common Stock [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)							6,910,283
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)							$ 4.75
Warrants in Connection with WAVI Credit Facility [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)						550,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)						$ 1.75
WAVI Holding AG and Taurus4757 GmbH Warrants [Member]
Stock Issued During Period, Shares, Cashless Warrant Exercises (in shares)		2,747,970
Class of Warrant or Right, Exercised During Period (in shares)		3,871,405	79,100	3,871,405
Warrants Exercised [Member]
Stock Issued During Period, Shares, Cashless Warrant Exercises (in shares)	70,030
Class of Warrant or Right, Exercised During Period (in shares)	79,100

Note 9 - Warrants - Summary of

Note 9 - Warrants - Summary of Warrant Activity (Details)	9 Months Ended
	Sep. 30, 2021$ / sharesshares
Outstanding, number of shares (in shares) | shares	79,100
Outstanding, weighted average exercise price (in dollars per share) | $ / shares	$ 4.75
Exercised, number of shares (in shares) | shares	(79,100)
Exercised, weighted average exercise price (in dollars per share) | $ / shares	$ 4.75
Outstanding, number of shares (in shares) | shares	0
Outstanding, weighted average exercise price (in dollars per share) | $ / shares	$ 0

Note 10 - Income Taxes (Details

Note 10 - Income Taxes (Details Textual) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2021	Sep. 01, 2021	Aug. 09, 2021	May 03, 2021
Income Tax Expense (Benefit), Total	$ (4,988)	$ 0	$ (17,540)	$ 0
Effective Income Tax Rate Reconciliation, Percent, Total	98.00%		161.00%
Discrete Tax Benefit			$ 8,500
Stock Compensation Windfall Tax Benefits	$ 3,100		$ 6,300
Effective Income Tax Rate Reconciliation, Before Discrete Items, Percent	18.00%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent			21.00%
Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount			$ (8,500)
GCI Acquisition [Member]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities								$ 23,526
Sexton Acquisition [Member]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities						$ 1,284	$ 1,300
Forecast [Member]
Deferred Tax Assets, Valuation Allowance, Total					$ 1,200

Note 11 - Net (Loss) Income P_3

Note 11 - Net (Loss) Income Per Common Share - Calculation of Diluted Shares (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Net income (loss)	$ 79	$ (1,133)	$ 6,837	$ 4,795
Amount attributable to unvested restricted shares	(2)	0	(212)	(138)
Amount attributable to warrants outstanding	0	0	(4)	(335)
Net income (loss) allocated to common shareholders	$ 77	$ (1,133)	$ 6,621	$ 4,322
Weighted-average common shares issued and outstanding (in shares)	40,911,801	31,639,420	37,435,224	25,418,375
Basic earnings (loss) per common share (in dollars per share)	$ 0	$ (0.04)	$ 0.18	$ 0.17
Amount attributable to unvested restricted shares	$ 2	$ 0	$ 205	$ 0
Amount attributable to warrants	0	0	4	49
Less: gain related to change in fair value of warrants	0	0	0	4,467
Diluted earnings (loss) per common share	$ 77	$ (1,133)	$ 6,628	$ 279
Stock options (in shares)	1,069,207	0	1,330,207	1,754,051
Restricted shares (in shares)	1,315,462	0	1,195,154	285,975
Warrants (in shares)	0	0	24,338	1,954,137
Diluted weighted average shares issued and outstanding (in shares)	43,296,470	31,639,420	39,984,923	29,412,538
Diluted earnings (loss) per common share (in dollars per share)	$ 0	$ (0.04)	$ 0.17	$ 0.01

Note 11 - Net (Loss) Income Com

Note 11 - Net (Loss) Income Common Share - Anti-dilutive Securities Excluded From Computation (Details) - shares	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Anti-dilutive securities (in shares)	0	2,246,306	0	0
Share-based Payment Arrangement, Option and Restricted Stock Awards [Member]
Anti-dilutive securities (in shares)	0	2,183,537	0	0
Warrant [Member]
Anti-dilutive securities (in shares)	0	62,769	0	0

Note 13 - Revenue - Revenues by

Note 13 - Revenue - Revenues by Product Line (Details) - USD ($) $ in Thousands	3 Months Ended				9 Months Ended
	Sep. 30, 2021		Sep. 30, 2020		Sep. 30, 2021		Sep. 30, 2020
Total revenue	$ 33,800	[1]	$ 11,279	[2]	$ 81,851	[2]	$ 33,361	[2]
Product, Freezer and Thaw [Member]
Total revenue	17,610		3,371		40,021		9,237
Product, Cell Processing [Member]
Total revenue	11,505		7,414		30,131		22,753
Product, Storage and Cold Chain Services [Member]
Total revenue	86		19		293		30
Service, Storage and Cold Chain Services [Member]
Total revenue	2,250		0		6,417		0
Rental, Storage and Cold Chain Services [Member]
Total revenue	$ 2,349		$ 475		$ 4,989		$ 1,341
[1]	2020 revenue includes service revenue related to SciSafe from October 1, 2020 through December 31, 2020.
[2]	2019 revenue includes automated thawing revenue related to Astero from April 1, 2019 through December 31, 2019; evo shipper rental revenue related to SAVSU from August 8, 2019 through December 31, 2019; and freezer and accessory revenue related to CBS from November 12, 2019 through December 31, 2019.

Note 13 - Revenue - Summary of

Note 13 - Revenue - Summary of Remaining Performance Obligations (Details) $ in Thousands	Sep. 30, 2021USD ($)
Rental Revenue [Member]
Service revenue, expected to be recognized in the future	$ 11,138
Service Revenue [Member]
Service revenue, expected to be recognized in the future	$ 112

Note 13 - Revenue - Summary o_2

Note 13 - Revenue - Summary of Remaining Performance Obligations 2 (Details) $ in Thousands	Sep. 30, 2021USD ($)
Rental Revenue [Member]
Service revenue, expected to be recognized in the future	$ 11,138
Rental Revenue [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2021-10-01
Service revenue, expected to be recognized in the future	$ 2,983
Service revenue, expected to be recognized in the future, period (Year)	3 months
Rental Revenue [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-01-01
Service revenue, expected to be recognized in the future	$ 7,733
Service revenue, expected to be recognized in the future, period (Year)	1 year
Rental Revenue [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-01-01
Service revenue, expected to be recognized in the future	$ 422
Service revenue, expected to be recognized in the future, period (Year)	1 year
Rental Revenue [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-01-01
Service revenue, expected to be recognized in the future	$ 0
Service revenue, expected to be recognized in the future, period (Year)	1 year
Service Revenue [Member]
Service revenue, expected to be recognized in the future	$ 112
Service Revenue [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2021-10-01
Service revenue, expected to be recognized in the future	$ 40
Service revenue, expected to be recognized in the future, period (Year)	3 months
Service Revenue [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-01-01
Service revenue, expected to be recognized in the future	$ 31
Service revenue, expected to be recognized in the future, period (Year)	1 year
Service Revenue [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-01-01
Service revenue, expected to be recognized in the future	$ 31
Service revenue, expected to be recognized in the future, period (Year)	1 year
Service Revenue [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-01-01
Service revenue, expected to be recognized in the future	$ 10
Service revenue, expected to be recognized in the future, period (Year)	1 year

Note 14 - Leases (Details Textu

Note 14 - Leases (Details Textual)	3 Months Ended		9 Months Ended
	Sep. 30, 2021USD ($)ft²a	Sep. 30, 2020USD ($)	Sep. 30, 2021USD ($)ft²a	Sep. 30, 2021EUR (€)ft²a	Sep. 30, 2020USD ($)
Operating Lease, Payments	$ 702,000	$ 219,000	$ 2,000,000		$ 653,000
Bothell, Washington Headquarters [Member]
Area of Real Estate Property (Square Foot) | ft²	32,106		32,106	32,106
Lease Agreement, Tenant Allowance			$ 2,600,000
Lessee, Operating Lease, Renewal Term (Year)	5 years		5 years	5 years
Monthly Base Rent Expense			$ 70,000
Menlo Park, California Location [Member]
Area of Real Estate Property (Square Foot) | ft²	3,460		3,460	3,460
Monthly Base Rent Expense			$ 11,000
Albuquerque, New Mexico Location [Member]
Area of Real Estate Property (Square Foot) | ft²	9,932		9,932	9,932
Lessee, Operating Lease, Renewal Term (Year)	3 years		3 years	3 years
Monthly Base Rent Expense			$ 9,000
Detroit, Michigan Location [Member]
Area of Real Estate Property (Square Foot) | ft²	106,998		106,998	106,998
Monthly Base Rent Expense			$ 35,000
United States, First Lease Agreement [Member]
Area of Real Estate Property (Square Foot) | ft²	16,800		16,800	16,800
Monthly Base Rent Expense			$ 14,000
United States, Second Lease Agreement [Member]
Area of Real Estate Property (Square Foot) | ft²	20,000		20,000	20,000
Monthly Base Rent Expense			$ 14,000
United States, Third Lease Agreement [Member]
Area of Real Estate Property (Square Foot) | a	12,500		12,500	12,500
Monthly Base Rent Expense			$ 8,000
The United States of America [Member]
Area of Real Estate Property (Square Foot) | ft²	16,153		16,153	16,153
Monthly Base Rent Expense			$ 13,000
The United States of America, Second Lease [Member]
Area of Real Estate Property (Square Foot) | ft²	26,800		26,800	26,800
Lessee, Operating Lease, Renewal Term (Year)	5 years		5 years	5 years
Monthly Base Rent Expense			$ 27,000
Lessee, Operating Lease, Yearly Rent Increase Percentage			2.50%	2.50%
The Netherlands Lease Agreement [Member]
Area of Real Estate Property (Square Foot) | a	47,533		47,533	47,533
Lessee, Operating Lease, Renewal Term (Year)	5 years		5 years	5 years
Monthly Base Rent Expense			$ 33,000	€ 29,000
Lease in Athens, Ohio [Member]
Area of Real Estate Property (Square Foot) | ft²	50,000		50,000	50,000
Monthly Base Rent Expense			$ 23,000
Lease in Columbus, Ohio [Member]
Area of Real Estate Property (Square Foot) | ft²	1,807		1,807	1,807
Monthly Base Rent Expense			$ 4,000
Lease in Nelsonville, Ohio [Member]
Area of Real Estate Property (Square Foot) | ft²	22,764		22,764	22,764
Monthly Base Rent Expense			$ 10,000
Indianapolis Indiana [Member]
Area of Real Estate Property (Square Foot) | ft²	11,415		11,415	11,415
Monthly Base Rent Expense			$ 13,000

Note 14 - Leases - Lease Term a

Note 14 - Leases - Lease Term and Discount Rate (Details)	Sep. 30, 2021	Dec. 31, 2020
Weighted average discount rate - operating leases	3.60%	3.30%
Weighted average discount rate - finance leases	6.10%	5.70%
Weighted average remaining lease term in years - operating leases (Year)	7 years 10 months 24 days	1 year 6 months
Weighted average remaining lease term in years - finance leases (Year)	3 years 2 months 12 days	10 months 24 days

Note 14 - Leases - Components o

Note 14 - Leases - Components of Lease Expense (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Operating lease costs	$ 805	$ 170	$ 1,998	$ 509
Short-term lease costs	498	59	1,158	176
Total operating lease costs	1,303	229	3,156	685
Variable lease costs	193	0	477	0
Total lease expense	$ 1,496	$ 229	$ 3,633	$ 685

Note 14 - Leases - Maturities o

Note 14 - Leases - Maturities of Lease Liabilities (Details) $ in Thousands	Sep. 30, 2021USD ($)
2021 (3 months remaining), operating leases	$ 890
2021 (3 months remaining), finance leases	43
2022, operating leases	3,108
2022, finance leases	171
2023, operating leases	2,760
2023. finance leases	171
2024, operating leases	2,523
2024, finance leases	101
2025, operating leases	2,245
2025, finance leases	37
Thereafter, operating leases	8,780
Thereafter, finance leases	1
Total operating lease payments	20,306
Total financing lease payments	524
Less: operating lease interest	(2,611)
Less: financing lease interest	(49)
Total present value of operating lease liabilities	17,695
Total present value of financing lease liabilities	$ 475

Note 15 - Unaudited Condensed_3

Note 15 - Unaudited Condensed Consolidated Balance Sheet Detail (Details Textual) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Depreciation, Total	$ 691,000	$ 296,000	$ 2,100,000	$ 873,000

Note 15 - Unaudited Condensed_4

Note 15 - Unaudited Condensed Consolidated Balance Sheet Detail - Property and Equipment (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Property and equipment	$ 23,639	$ 13,962
Less: Accumulated depreciation	(6,177)	(3,842)
Net property and equipment	17,462	10,120
Leasehold Improvements [Member]
Property and equipment	3,301	2,393
Furniture and Computer Equipment [Member]
Property and equipment	1,793	902
Manufacturing Facility [Member]
Property and equipment	13,798	10,076
Construction in Progress [Member]
Property and equipment	$ 4,747	$ 591

Note 15 - Unaudited Condensed_5

Note 15 - Unaudited Condensed Consolidated Balance Sheet Detail - Accrued Liabilities and Other Current Liabilities (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Accrued expenses	$ 1,435	$ 472
Accrued taxes	62	112
Accrued compensation	4,167	2,898
Warranty reserve liability	5,552	212
Deferred revenue, current	710	931
Other	131	130
Total accrued expenses and other current liabilities	$ 12,057	$ 4,755

Note 15 - Unaudited Condensed_6

Note 15 - Unaudited Condensed Consolidated Balance Sheet Detail - Warranty Reserve Liability (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Beginning balance	$ 212	$ 191
Warranty reserve acquired in the acquisition of Global Cooling	3,353	0
Provision for warranties	4,446	109
Settlements of warranty claims	(2,459)	(92)
Ending Balance	$ 5,552	$ 208

Note 16 - Employee Benefit Pl_2

Note 16 - Employee Benefit Plan (Details Textual) - Defined Contribution Plan, 401 K [Member] - Pension Plan [Member] - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay			100.00%
Defined Contribution Plan, Employer Discretionary Contribution Amount	$ 237,000	$ 89,000	$ 587,000	$ 268,000

Note 17 - Subsequent Events (De

Note 17 - Subsequent Events (Details Textual)	Oct. 31, 2021USD ($)	Oct. 08, 2021USD ($)ft²	Sep. 30, 2021USD ($)
Albuquerque, New Mexico Location [Member]
Monthly Base Rent Expense			$ 9,000
Subsequent Event [Member] | Bothell Washington Headquarters 2 [Member]
Area of Leased Real Estate Property Increase (Decrease) (Square Foot) | ft²		8,342
Lease Agreement, Tenant Allowance		$ 417,000
Monthly Base Rent Increase (Decrease)		$ 19,000
Lease Obligation Incurred, Percentage, Annual Increase		3.00%
Subsequent Event [Member] | Albuquerque, New Mexico Location [Member]
Monthly Base Rent Expense	$ 10,000